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Abstract: Delayed onset muscle soreness (DOMS) is discomfort that occurs within 8-
24hrs following an unaccustomed or high-intensity bout of physical activity that peaks 
within 24-27hrs and slowly resolves on its own. A popular treatment in alleviating the 
pain associated with DOMS is the consumption of NSAIDs such as aspirin which 
increases the risk of gastrointestinal (GI) injury upset. White willow bark (WWB) is a 
nutritional supplement that is believed to have anti-inflammatory and analgesic properties 
like aspirin but without the risk of GI adverse effects. The purpose of this investigation is 
to determine the effectiveness of WWB on alleviating the symptoms of DOMS following 
exercise. Twenty-five individuals volunteered to participate and were randomly assigned 
to take WWB (798mg salicin) or placebo for 5 days following a lower body resistance 
training session which consisted of 5X10 lunges at 40% body weight (BW) and 
3Xfatigue leg press at 75%BW. Test procedures included Visual Analog Scale (VAS), 
mid-thigh circumference, pressure pain threshold, vertical jump height, ground-contact 
time, peak power, and peak velocity. VAS was measured pre, days1-5 of the 
supplementation period and day 6 (post). All other variables were measured at pre, 
immediate, day 3(72hrs), and day 6 (post). Twelve two-way repeated measure ANOVAs 
were utilized in this investigation. No condition X time interaction was observed (p > 
0.05) for any variable. However, VAS scores were lower in the WWB compared to the 
placebo for all time frames. There was a significant main effect of time for VAS scores 
indicating muscle soreness for hamstrings (p < 0.001), gluteal (p < 0.001), gastrocnemius 
(p < 0.001) and quadriceps (p < 0.001). In addition, there was a significant main effect of 
time for right mid-thigh pressure pain threshold (p = 0.02), mid-right (p < 0.001) and 
mid-left (p < 0.001) thigh circumference, jump height (p < 0.001), ground contact time (p 
< 0.001), peak power (p < 0.001), and peak velocity (p < 0.001). These findings conclude 
WWB may reduce subjective feelings of muscle soreness. However, the ability of WWB 





TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION ......................................................................................................1 
 
1.1. Introduction .......................................................................................................1 
1.2. Purpose of Study ...............................................................................................5 
1.3. Specific Aim .....................................................................................................5 
1.4. Research Questions ...........................................................................................6 
1.5. Hypothesis.........................................................................................................6 
1.6. Significance of Study ........................................................................................6 
1.7. Delimitations .....................................................................................................8 
1.8. Limitations ........................................................................................................8 




II. REVIEW OF LITERATURE..................................................................................11 
  
 2.1. Aspirin.............................................................................................................12 
        2.1.1. Recommended Dosage of Aspirin ........................................................12 
        2.1.2. Proposed Mechanism for Ant-inflammatory and Analgesic Effects ....12 
        2.1.3. Adverse Effects Associated with Aspirin .............................................13 
 2.2 Willow Bark (Salix aba L.) ..............................................................................14 
        2.2.1 History of Willow Bark .........................................................................15 
        2.2.2. Willow Bark’s Proposed Mechanism of Action ...................................16 
        2.2.3. Components of Willow Bark ................................................................19 
        2.2.4. Recommended Dosage and Regulation ................................................21 
 2.3. Effectiveness of Willow Bark in Decreasing Pain ..........................................22 
       2.3.1. Low Back Pain .......................................................................................22 
       2.3.2. Arthritic Conditions ...............................................................................25 
       2.3.3. Summary of “Effectiveness of Willow Bark in Decreasing Pain” ........30 
     2.4. Adverse Effects Associated with Willow Bark Compared to NSAIDs ...........31 
            2.4.1. Willow Bark and Platelet Aggregation ..................................................32 
       2.4.2. Reported Adverse Effects with Willow Bark ........................................32 
       2.4.3. Conclusion of Willow Barks Adverse Effects .......................................36 
 
 
III. METHODOLOGY ................................................................................................37 
vi 
 
Chapter                                                                                                                     Page 
  
      3.1. Introduction .....................................................................................................37 
 3.2. Participants ......................................................................................................38 
 3.3. Study Design ...................................................................................................38 
 3.4. Instruments and Procedures  ...........................................................................40 
        3.4.1. Height and Weight  ...............................................................................40 
           3.4.2. Visual Analog Scale ..............................................................................40 
             3.4.3. Mid-Thigh Circumference ....................................................................41 
        3.4.4. Pressure Pain Threshold ........................................................................41 
        3.4.5. Four Repeated Countermovement Jumps .............................................42 
             3.4.6. Fatiguing Protocol .................................................................................43 
             3.4.7. Treatment Conditions............................................................................43 
             3.4.8. Statistical Analysis ................................................................................44 
 
 
IV. RESULTS ..............................................................................................................47 
 
 4.1. Descriptive Statistics .......................................................................................47 
 4.2. Muscle Soreness and Discomfort....................................................................48 
        4.2.1. Hamstrings Muscle Soreness ................................................................48 
        4.2.2. Gluteal Muscle Soreness .......................................................................48 
        4.2.3. Gastrocnemius Muscle Soreness...........................................................49 
             4.2.4. Quadriceps Muscle Soreness ................................................................50 
     4.3. Pressure Pain Threshold ...................................................................................53 
     4.4. Mid-Thigh Circumference ...............................................................................54 
     4.5. Athletic Performance .......................................................................................57 
       4.5.1. Jump Height ...........................................................................................57 
            4.5.2. Ground Contact Time ............................................................................58  
            4.5.3. Peak Power.............................................................................................58 
      4.5.4. Peak Velocity ..........................................................................................59 
 
V.  DISCUSSION ........................................................................................................62 
 
 5.1. Muscle Soreness and Discomfort....................................................................63 
 5.2. Pressure Pain Threshold ..................................................................................64 
 5.3. Mid-Thigh Circumference ..............................................................................65 
 5.4. Athletic Performance ......................................................................................66 






 APPENDIX A: Health History Questionnaire .......................................................81 
 APPENDIX B: Visual Analog Scale .....................................................................84 
vii 
 
 Chapter                                                                                                                     Page 
 




LIST OF TABLES 
 
 
Table           Page 
 
1. Demographic Data ..............................................................................................47 
2. VAS for Hamstrings, Gluteal, Gastrocnemius, and Quadriceps .........................52 
3. Effect Size (d) Between Days for Subjective Muscle Soreness………………..53 
4. Parameters of Muscle Damage Measured Prior and Following DOMS .............56 
5. Effect Size (d) Between Days for Parameters of DOMS………………………57 
6. Athletic Performance Parameters Measured Prior and Following DOMS .........60 
7. Effect Size (d) Between Days for Athletic Performance…………………….…61 
                     
ix 
 
LIST OF FIGURES 
 
Figure           Page 
 
1. Schematic of Possible Sequence of Injury Leading to DOMS and Treatment .....3 
2. COX Inflammatory Pathway and Actions of NSAIDs on Pathway ...................13 
3. Experimental Design ...........................................................................................40 
4. VAS Hamstrings .................................................................................................48 
5. VAS Gluteal Muscles .........................................................................................49 
6. VAS Gastrocnemius............................................................................................50 
7. VAS Quadriceps .................................................................................................51 
8. Pressure Pain Threshold Right Mid-Thigh .........................................................53 
9. Pressure Pain Threshold Left Mid-Thigh ...........................................................54 
10.  Right Mid-Thigh Circumference .......................................................................55 
11.  Left Mid-Thigh Circumference..........................................................................55 
12.  Jump Height .......................................................................................................57 
13.  Ground Contact Time ........................................................................................58 
14.  Peak Power.........................................................................................................59 
15.  Peak Velocity .....................................................................................................60 









Delayed onset muscle soreness (DOMS) is defined as pain or discomfort that occurs after 
an unaccustomed or high-intensity bout of physical activity (Cheung et al., 2003). Individuals of 
all fitness levels (athletes to novice) can experience DOMS following exercise. Clinically, DOMS 
is considered as a type 1 muscle strain (Safran et al., 1989). Following an extensive training 
session, DOMS will typically occur within 8-24 hours, peak within 24-72 hours following 
exercise and slowly resolves on its own within 5-7 days (Manimmanakorn et al., 2016; 
Ranchordas et al., 2020). The duration for healing is dependent on the severity of the muscle 
damage and the fitness level of the individual (Cheung et al., 2003; Smith, 1992). Eccentric 
exercise is well documented as the culprit of DOMS (Proske & Morgan, 2001). An eccentric 
muscle contraction occurs when the muscle is forcibly lengthened while actively developing 
tension (Davis et al., 2007; Proske & Morgan, 2001). Any exercise that contains an eccentric 
component (plyometric exercise, squatting, jumping, downhill running, and the lowering phase of 
resistance training) will produce greater amounts of muscle fiber damage, inflammation, DOMS, 
and muscle function deficits (Davis et al., 2007).
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The underlying cause of DOMS is not fully understood. Most researchers agree that 
DOMS is caused by muscle damage (sarcomere disruption) and inflammation (Amalraj, Divya, & 
Gopi, 2020; Hoseinzadeh, Daryanoosh, Baghdasar, & Alizadeh, 2015) (Figure 1). During 
eccentric exercise, the sarcomeres become overstretched and following exercise fail to return to 
their resting length (Brooks et al., 2005). The overstretched sarcomeres allow calcium to 
accumulate into the injured portion of the muscle (Cheung, Hume, & Maxwell, 2003;Maclntosh 
et al., 2006). The influx of calcium initiates a surge of signaling that activates both proteases and 
phospholipases resulting in the production of both prostaglandins and leukotrienes (Cheung, 
Hume, & Maxwell, 2003;Maclntosh et al., 2006). The leukotrienes increase vascular permeability 
allowing fluids and intracellular components to enter the cells and neutrophils to invade the area 
of muscle damage (Maclntosh et al., 2006). The fluids and intracellular components attract 
macrophages to the injured area (Maclntosh et al., 2006). The invasion of macrophages stimulates 
free radicals, proinflammatory cytokines (IL-6 and IL-1), and tumor necrosis factor (TNF) 
production that enhance muscle injury and the chemical stimulation of type II and IV muscle 
afferent pain receptors resulting in DOMS (Connolly, Sayers, & McHugh, 2003; Maclntosh, 
Gardiner, & McComas, 2006). The most popular pathway that is proposed to result in DOMS 
involves the arachidonic acid pathway. Following muscle injury, arachidonic acid is released 
from the damaged cellular membranes (Maroon, Bost, Borden, Lorenz, & Ross, 2006). Once 
released, arachidonic acid is quickly transformed into prostaglandins (PGE2) and thromboxane 
through the enzyme cyclooxygenase (COX-1 or COX-2) (Maroon, Bost, Borden, Lorenz, & 
Ross, 2006). COX-1 is a constitutive enzyme that protects the gastrointestinal lining and aids in 
platelet aggregation (Maroon, Bost, Borden, Lorenz, & Ross, 2006). In comparison, COX-2 is 
only activated during muscle damage and aids in the production of inflammation and stimulation 






The sensation of pain can deter an individual from adhering to an exercise program, 
interfere with activities of daily living, and decrease athletic performance (Ranchordas et al., 
2020). Since the mechanism that results in DOMS is not agreed upon, there are many different 
treatment strategies used in hopes of alleviating pain and maintaining athletic performance. Some 
techniques used to decrease DOMS include massage (Andersen et al., 2013; Farr et al., 2002; 
Mancinelli et al., 2006; Zainuddin et al., 2005), heat therapy (Petrofsky, 2013; Petrofsky et al., 
2017; Symons et al., 2004) hydrotherapy (Bailey et al., 2007; Sellwood et al., 2005; Vaile et al., 
2008), and non-steroidal anti-inflammatory drugs ( NSAIDs) (Barlas et al., 2000; Hasson et al., 
1993; Meamarbashi & Rajabi, 2015; Riasati et al., 2010; Stone et al., 2002; Tokmakidis et al., 
2003). The results of the studies examining different strategies to alleviate DOMS and maintain 
muscle function following an exhaustive bout of eccentric exercise are mixed. A possible reason 
for the inconclusive results is a lack of understanding of the exact mechanism responsible for 
DOMS and the treatment strategy for DOMS may vary between individuals (Hart et al., 2005).  
Figure 1- Schematic showing the possible sequence of injury leading to DOMS and Treatment. COX-2, 
cycloxygenase; PGE2; prostaglandin E2 . Adapted from “The Treatment and Prevention of Delayed Onset Muscle 
Soreness,” by Connolly, D.A.J., Sayers, P., & McHugh, M.P. 2003. Journal of Strength and conditioning, 17(1), p. 





The consumption of NSAIDs or analgesics is the most popular method to treat post 
exercise pain and soreness (Brewer et al., 2014). Many studies have been conducted to discover 
the effects of various NSAIDs such as aspirin (Riasati et al., 2010) ibuprofen (Hasson et al., 1993; 
Stone et al., 2002; Tokmakidis et al., 2003) and indomethacin (Meamarbashi & Rajabi, 2015) and 
analgesics such as paracetamol (Barlas et al., 2000) on the parameters of DOMS following 
exercise. Some studies show that NSAIDs decrease DOMS (Riasati et al, 2010; Hasson et al., 
1993; Tokmakidis et al., 2003) while other’s (Barlas et al., 2000; Meamarbashi & Rajabi, 2015; 
Stone et al., 2002) concluded that NSAIDs have no effect of DOMS. A survey examining the 
prevalence of NSAIDs and non-narcotic analgesics use in the United States found that 
approximately 14% of adults use non-narcotic analgesics daily for pain relief from 
musculoskeletal injuries and other aliments (Paulose-Ram et al., 2005). Specifically examining 
colligate athletes, the prevalence of NSAIDs or other non-narcotic analgesics ranges from 17-
83% (Brewer et al., 2014). The most common medications used to treat musculoskeletal pain and 
soreness is acetaminophen, aspirin, and ibuprofen (Brewer et al., 2014). Remarkably, individuals 
who use NSAIDs or analgesics daily are not bothered by the potential side effects of taking the 
medication compared to those who take either medication on an acute basis (Wilcox et al., 2005). 
The use of NSAIDs poses a risk of experiencing adverse effects with a higher risk in those who 
chronically use NSAIDs. The potential adverse effects associated with NSAIDs include 
gastrointestinal injuries, gastrointestinal upset, increased risk of blood clots, stroke and liver and 
kidney injury.  
Due to the potential side effects, there has been extensive research done on potentially 
using nutritional supplements in the alleviation of DOMS and other musculoskeletal issues. It is 
theorized that nutritional supplements have similar anti-inflammatory properties of NSAIDs 
without the risk of adverse effects and may be an alternative to NSAIDs in controlling 
inflammation and oxidative stress following exercise (Nakhostin-Roohi, Moradlou, Hamidabad, 
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& Ghanivand, 2016). The supplements that may be an alternative to NSAIDs include curcumin, 
ginger, ginseng, protease, green tea extract and pomegranate. Like the other techniques (i.e., 
massage, hydrotherapy, heat, and stretching) used to treat DOMS, the results from the numerous 
studies examining the above-mentioned supplements are mixed. One of the main reasons of the 
disparity is due the absences of a uniform recommended dosage and duration for the consumption 
of the supplements for maximal anti-inflammatory and analgesic effects. 
 
1.2 Purpose of Study 
Previous research has examined the effects of nutritional supplements such as curcumin, 
ginger, ginseng, protease, green tea extract, and pomegranate on their ability to alleviate delayed 
onset muscle soreness and maintaining athletic performance.  To the best of our knowledge, no 
studies to date, have examined the potential of the nutritional supplement white willow bark 
(WWB) as an alternative to NSAIDs or analgesics to decrease pain and inflammation associated 
with muscle damage. Therefore, the purpose of this study is to investigate the effectiveness of 
WWB on alleviating the symptoms of DOMS following exercise. 
 
1.3 Specific Aims 
1. The first aim was to investigate if WWB has any effect on the parameters of DOMS 
(perceived pain/soreness and thigh swelling) compared to placebo following an 
exhaustive lower body resistance training session. 
2. The second aim was to determine if WWB could maintain athletic performance 
(vertical jump height) following an exhaustive lower body resistance training session. 
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1.4 Research Questions 
1. Does WWB decrease DOMS compared to placebo following an exhaustive lower body 
resistance training session? 
2. Does WWB maintain sport performance (vertical jump height) compared to placebo 
following an exhaustive lower body resistance training session? 
 
1.5 Hypothesis 
1. HO: There will be no difference between the placebo and WWB in parameters of 
DOMS following a damaging lower body resistance training session. 
HA: There will be a significant difference between the placebo and WWB in 
parameters of DOMS following a damaging lower body resistance training 
session. 
2.  HO: No difference between the placebo and WWB in athletic performance 
(vertical jump height) following a damaging lower body resistance training 
session. 
HA: There will be a significant difference between the placebo and WWB in sport 
performance (vertical jump height) following a damaging lower body resistance 
training session. 
 
1.6 Significance of Study 
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In the United States in 2000, 111 million NSAID prescriptions were written by 
physicians for the treatment of musculoskeletal pain (Laine, 2001). A recent study has shown that 
14 million Americans use NSAIDs for minor muscle aches and another 36 million use NSAIDs 
for the treatment of pain (Wilcox et al., 2005). Surprisingly, many of the long-term users are not 
concerned with the adverse effects that are common with the consumption of NSAIDs. In 
addition, each year approximately 100,000 individuals are hospitalized for gastrointestinal 
complications resulting from the use of NSAIDs with a cost ranging from $1,800-8,500 per 
hospital stay (Fine, 2013). It is projected that the use of NSAIDs is going to continue to rise in the 
United States because of an increase in life expectancy (Fine, 2013). Americans are living longer 
today due to the advancement in health care. With aging comes the increase risk of chronic pain 
and other conditions that require either an acute or chronic use of NSAIDs for treatment. 
Consequently, the increase use of NSAIDs is correlated with an increased risk of adverse effects. 
Therefore, it is imperative to identify alternatives to aspirin and other NSAIDs that offer the 
similar analgesic and anti-inflammatory effects without the risk of adverse effects. One of those 
potential alternatives to aspirin and other NSAIDs is WWB. 
To date, literature examining the effects of WWB has been done only on a clinical 
population, such as those with osteoarthritis, chronic low back pain, and rheumatoid arthritis. 
Studies examining the effects of willow bark on perceive pain and inflammation have been sparse 
with results showing a potential for willow bark as a safer or tolerable alternative to NSAIDs. The 
current study has the potential to discover an alternative to NSAIDs or analgesics in the 
management of DOMS and other minor musculoskeletal injuries. If successful, WWB may serve 
as an alternative to NSAIDs in those individuals who take NSAIDs for the occasional muscle 





1. Participants were limited to 18-35 years of age. 
2. This investigation required the recruitment of approximately 30 males and females to 
complete the study. 
3. All participants were required to be healthy and free from any sign or symptom of 
disease, and be without any musculoskeletal injury, previous surgery within the last 6 
months (i.e., hip, low back, knee, and ankle), without a diagnosis of all types of arthritis 
(i.e., osteoarthritis, gout, rheumatoid arthritis etc.) or have chronic low back pain. 
4. This investigation required the participants to not be participating in a low body 
resistance program on a regular basics (at least 3 days a week for the last 3 months).  
5. This investigation required the participants to refrain from participating in any exercise or 
physical activity program involving the lower body during the duration of the study. 
6. The investigation required that the participants refrain from taking any NSAIDs, 
analgesics, corticosteroids, or any type of nutritional aid that could interfere with the 
therapeutic actions of WWB.  
7. All participants were not taking medication that may interfere with WWB (i.e., 
anticoagulants, beta blockers, diuretic, methotrexate, or phenytoin). 
8. The investigation required that all participants not have a known allergy or sensitivity to 
salicylates such as aspirin. 
 
1.8 Limitations 
1. Participants were recruited through responding to a classroom visit, recorded Zoom 
video, poster flyer, and word of mouth. Therefore, this was a convenience sample. 
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2. The investigators had no control on the participants’ level of motivation during each visit 
which may have influenced their ability or level of effort when performing the vertical 
jump. 
3. The investigators could not control for any influence such as activity, diet, timing of 
WWB intake, and/or sleep outside of the visits, which may have impacted the results of 
the study. 
4. The investigators could not control when the participants filled out their visual analog 
scale each morning to rate their muscle soreness/discomfort which may have impacted 
the results of the study. 
 
1.9 Assumptions 
1. The participants were truthful when answering the questions on the health history and       
exercise questionnaire 
2. The participants were not participating lower body resistance program on a regular 
basis that included: leg extension, squats, leg press, lunges, dead-lift, or hamstring curls. 
3. The participants were taking the WWB or placebo as directed ( 2 tablets 3 times daily 
with food) during the supplementation period. 
4. The participants were truthful and filled out their visual analog scale to rate their pain 
and discomfort within 30 minutes of waking each morning. 
5.  The fatiguing protocol used in the investigation was effective in inducing acute 
muscle damage resulting in DOMS. 
6. The participants did not take any NSAIDs or other analgesic medication (prescription, 
over-the counter or nutritional aids) and did not participant in any technique (i.ec., 
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massage, heat, topical creams, stretching, exercise, or hydrotherapy) that had the potential 
to decrease DOMS for the duration of the study. 
7. The technology and equipment utilized for data collection functioned as intended by 
the manufacturers.  



























REVIEW OF LITERATURE 
 
The aim of this review of literature is to examine aspirin and the mechanism it acts upon 
to decrease pain and inflammation. In addition, the adverse effects of aspirin are examined 
justifying the need to find more natural remedies to alleviate pain and inflammation. The history 
of willow bark and the proposed mechanism that willow bark acts upon to decrease pain will be 
reviewed. In addition, studies investigating the efficacy of willow bark in the treatment of 
musculoskeletal disorders are examined.  
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2.1 Aspirin  
 
2.1.1 Recommended Dosage of Aspirin  
Salicylates such as aspirin are one of the oldest and most common drugs consumed by 
man because of its antipyretic, anti-inflammatory, and analgesic effects. Approximately 100,000 
Americans over the age of 40 consume aspirin everyday (Kim & Beckles, 2004). Aspirin has 
many beneficial uses such as decreasing the risk of heart attacks in those with cardiovascular 
disease and preventing transient-ischemic attacks and stroke. Therefore, many Americans 
consume aspirin for the primary of secondary prevention of cardiovascular disease (Ittaman et al., 
2014). In addition, aspirin has been shown to decrease the risk of developing colon and rectum 
cancer (Ugurlucan et al., 2012). The dose of aspirin consumed often dictates whether an 
individual receives a cardioprotective or an analgesic effect. Typically, a low dose ranging from 
75-325mg per day is associated with a cardioprotective effect used in the primary and secondary 
prevention of cardiovascular disease (Sostres & Lanas, 2011). A dose greater than 325mg is often 
recommended for pain relief (Sostres & Lanas, 2011). 
 
2.1.2 Proposed Mechanism for Anti-inflammatory and Analgesic Effects 
It is theorized that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) acts 
upon the arachidonic acid pathway to slow the inflammation cascade (Figure 2). Aspirin and 
NSAIDs decrease pain and inflammation by the inhibition of the cyclo-oxygenase (COX) 
enzymes which catalyze the conversion of arachidonic acid (AA) to proinflammatory 
prostaglandin E2 (Vane & Botting, 1998). There are two main forms of the cyclo-oxygenase 
enzyme, COX-1 and CO-2. COX-1 is a constitutive enzyme that protects the gastrointestinal 
lining and aids in platelet aggregation (Maroon et al., 2006). In comparison, COX-2 is only 
13 
 
activated following muscle damage and facilitates the production of inflammation and stimulation 
of type II and IV pain receptors (Maroon et al., 2006). Both COX isoforms catalyze the 
conversion of arachidonic acid to prostaglandins (Lanier, 2003). Aspirin preferentially inhibits 
COX-1 over COX-2 (Lanier, 2003; Sostres & Lanas, 2011). Unlike other NSAIDS, aspirin is also 
believed to inhibit the synthesis of prostaglandin E2 by the irreversible acetylation of COX-1. 
Prostaglandin E2 serves as key mediator of acute inflammation. (Vane & Botting, 1998). 
Prostaglandin E2 and prostacyclin are vasodilators that act in sync with bradykinin and histamine 




2.1.3 Adverse Effects Associated with Aspirin 
The use of aspirin for most of its therapeutic effects does not come without risk. One of 
the most common adverse effects in those that consume aspirin is gastrointestinal upset or injury 
(Cryer, 2010; Sostres & Lanas, 2011). Unknown to the consumer, each time they take an aspirin 
Figure 2- COX inflammatory pathway from muscle damage and the proposed mechanisms of aspirin 
and NSAID action on the process. Adapted from “The Use of Nonsteroidal Anti-Inflammatory Drugs 
for Exercise- Induced Muscle Damage,” by B.J Schoenfeld, 2012, Sports Medicine, 42(12), p. 1091. 
Copyright 2012 by Springer International Publishing AG. 
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they are subjected to small breaks in the epithelial lining which resolves quickly own its own 
(Silen & Ito, 1985). If the damage is severe enough to penetrate the mucosa repair is typically 
achieved within 1-3 days. More serious injuries such as gastrointestinal lesions or ulcers can take 
weeks up to months to heal (Silen & Ito, 1985). Within in the general population, those who 
consume aspirin on a regular basics, have a two-fold increase in developing a gastrointestinal 
bleed (Cryer, 2010; Weil et al., 1995). In addition, 15% of individuals who consume aspirin with 
a history of bleeding stomach ulcers will have a recurrent bleed within one year of the initial 
event (Cryer, 2010; Weil et al., 1995). 
Gastrointestinal injury can occur through two different mechanisms, topical mucosal 
injury, or systematic effects (Cryer, 2010). Topical mucosal injury is due to local effects within 
the gastrointestinal mucosa. When the gastroduodenal mucosa comes into direct contact with 
aspirin it can result in damage by disrupting the gastric epithelial cell barrier (Tomisato et al., 
2004). Surprisingly, this can occur within minutes of expose to acetylated salicylate acid (aspirin) 
(Tomisato et al., 2004). Systemic effects leading to gastrointestinal injury is mediated by the 
inhibition of COX-1. The blocking of COX-1 depletes gastrointestinal mucosal prostaglandins 
inhibiting basal gastric acid and stimulates gastric acid secretion (Jaramillo et al., 1989). The 
systematic effects are the main mechanism that leads to damage in the upper gastrointestinal 
mucosa (Darling et al., 2004). The adverse effects of aspirin are not limited to the gastrointestinal 
system. The use of aspirin and other NSAIDs can lead to both liver and renal injury in addition to 
the accelerated development of heart failure in those who are already at risk (Lanier, 2003; Page 
& Henry, 2000). 
 
2.2 Willow Bark (Salix aba L.) 
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2.2.1 History of Willow Bark        
 Willow bark (Salix alba L.) is obtained from the whole or fragmented dried bark of 
young (2-3 years old) branches or twigs from various species of Salix belonging to the Salicaceae 
family (Viltrakyte, 2008). The bark of the willow tree contains no more than 1% total salicin 
derivatives which is calculated based upon salicin in relation to the dried herb (Viltrakyte, 
2008).Worldwide, there are approximately 400 willow species with the Salix species located in 
the North Temperature and Arctic regions (Lévesque & Lafont, 2000; Saller et al., 2008; Wood, 
2015). 
 Historical records show that willow bark has been used for thousands of years in ancient 
China, Egypt, Greece, and South Asia to alleviate headaches, fever, pain and in the treatment of 
numerous other illnesses (Oketch-Rabah et al., 2019). The Sumerians were the first to document 
the use of willow bark as a prescription for pain on clay tablets approximately 4,000 years ago 
(Wood, 2015). In 4th Century BC, Hippocrates, the father of medicine, instructed patients to chew 
the bark from the willow tree or drink the powder extract to relieve fever, pain, and inflammation 
(Oketch-Rabah et al., 2019). In addition, it is documented that the Babylonians chewed the leaf 
extract or bark from the willow tree as a remedy for pain, inflammation, and fever (Wood, 2015). 
The first modern medical documentation of the effect of willow bark occurred in 1763 when a 
priest named Edward Stone published the medical report in the Philosophical Transactions of the 
Royal Society on the effectiveness of willow bark in decreasing fever (Ugurlucan et al., 2012). 
Stone proposed that the English white willow bark could yield a treatment to rheumatic diseases 
and cure malaria. To test his theory, Stone dried out bark from the white willow tree and shifted 
the bark into a fine powder. Stone took approximately 20g of the powder every four hours and 
discovered that his fever and accompanying symptoms was eradicated with the treatment with no 
side effects (Stone, 1776). For the next five years, Stone tested the powdered willow bark extract 
on participants and concluded that consuming approximately 3.5g of white willow bark extract 
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(approximately 2% salicylates) was effective in decreasing fever associated with malaria (Stone, 
1775; Woods, 2015). 
The transition from folk medicine to lucrative medicine occurred in 1827 when the 
Johann Buchner isolated the pharmacological active ingredient salicin from the bark of the 
willow tree and in 1829 the French chemist Henri Leroux obtained 30g of salicin from 1.5kg 
willow bark (Ugurlucan et al., 2012). Following the discovery of salicin, in 1838, an Italian 
chemist Raffaele Piria split the salicin into a sugar and an aromatic component by creating 
salicylic acid (Mahdi, 2010). The willow bark era ended in 1860 when the chemists Kolbe and 
Lautemann discovered how to synthetically produce salicylic acid leading to the mass, 
commercial production of salicylic acid (Viltrakyte, 2008). During the 19th century, physicians 
prescribed either salicin or salicylic acid in the treatment of rheumatic fever, gout and as an 
antipyretic and analgesic drug (Wood, 2015).While effective in treating the forementioned 
conditions, the typical doses prescribed (8-10g daily) often resulted in gastric irritation and upset 
(Saller et al., 2008). To offset the adverse effects of synthetically produced salicylic acid, Bayer 
chemists set out to produce a stable acetylated salicylate which is known worldwide today as 
Aspirin (Saller et al., 2008). 
 
2.2.2 Willow Bark’s Proposed Mechanism of Action 
One of the active ingredients in willow bark is salicin. The prodrug salicin is stable in 
acidic conditions such as the human saliva (Bonaterra et al., 2010). Once ingested, through 
hydrolysis and β-glucuronidase salicin is converted to saligenin in the stomach and is further 
broken down to salicylic acid in the liver by the cytochrome P 450 system (Bonaterra et al., 
2010). Akao, Yoshino, Kobashi, and Hattorui (2002) conducted a study to compared salicin, 
saligenin, and salicylic acid in three different experiments. The researchers examined the 
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absorption of salicin and its derivatives after oral consumption in rats. After oral ingestion, 
salicylic acid appeared in blood plasma rapidly and was dose dependent. In comparison, when the 
rats orally ingested salicin, salicylic acid appeared slowly and no saligenin was detected. 
Interestingly, the researchers found when salicin was administered orally, salicin itself was poorly 
absorbed in the small intestine and was only absorbed once it ransformed into saligenin. In rats, 
once salicin is transformed into saligenin by bacteria in the intestine it is quickly transformed into 
salicylic acid. In rats, low levels of salicylic acid were maintained up to 17 hours. Based on this 
study, the researchers concluded that salicin appears to be activated gradually in rats. As of date, 
the absorption of the active ingredient salicin has not been studied in humans. However, it is 
speculated that in humans, the absorption of salicin is like that of rats.  
It is theorized that willow bark and its constitutes have inhibitory actions on the 
arachidonic acid pathway. More specifically, willow bark may target COX-1 and COX-2, to 
decrease pain and inflammation like aspirin. Recently, it has been found that many different 
compounds in addition to salicin exists in willow bark. Therefore, the exact mechanism in which 
willow barks upon to produce both anti-inflammatory and analgesic effects is not agreed upon. 
Through mechanism studies done in both in vitro and vivo, willow bark is believed to inhibit 
lipoxygenase, (Bonaterra et al., 2010; Fiebich & Chrubasik, 2004), inhibit COX-2 (Bonaterra et 
al., 2010; Fiebich & Chrubasik, 2004), prevent cytokine release (Altinterim, 2013), and have 
antioxidant effects (Ishikado et al 2013; Khayyal et al 2005) which contributes to its overall 
pharmacological effects (Ishikado et al., 2013). Many studies have been conducted to determine 
the effects of willow bark on the various mediators of the inflammatory cascade. For instance, in 
a vitro study, Bonaterra et al (2010) revealed that the aqueous willow bark extract (STW 33-I) 
significantly inhibits the pro-inflammatory cytokines, tumor necrosis factor alpha (TNFα), COX-
2 and nuclear translocation factor (NFκβ). These results support the assumption that willow bark 
has an inhibitory effect on the arachidonic acid pathway. Khayyal et al (2005) conducted a in 
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vivo study to discover willow barks role as an anti-inflammatory agent in rats under two 
conditions that represented both chronic and acute arthritis. Willow bark extract was compared to 
the anti-inflammatory doses of both aspirin (non-selective COX inhibitor) and celecoxib 
(selective COX-2 inhibitor). The authors found that willow bark was just as effective as aspirin in 
decreasing inflammation and suppressing prostaglandin release and more effective than aspirin in 
inhibiting COX-2. In addition, willow bark extract displayed superiority over both aspirin and 
celecoxib in the protection against oxidative stress.  
Fiebick and Chrubasik (2004) conducted a study in vitro to discover the effects of willow 
bark on human monocytes. The effects of the willow bark extract, salicin, and salicylate on 
selective cytokines (IL-6, and IL-β) and COX-2 mediated PGE2 release was evaluated against a 
Rofecoxib (selective COX-2 inhibitor) like compound. Compared to Rofecoxib like compound, 
significantly more willow bark extract was needed to inhibit the COX-2 mediated PGE2 while 
salicin and salicylate acid alone had no effect on inhibiting COX-2 or cytokine release. The 
results also demonstrated that neither salicin nor salicylate acid influenced COX enzyme activity. 
Based on this observation, the researchers speculated that willow bark extract influences COX 
enzyme activity through the inhibition of phospholipase A2 (PLA2) which produces arachidonic 
acid (the substrate of COX). Lastly, the researchers discovered that the willow bark extract 
successfully inhibited both the release of cytokines IL-1β and IL-6 while the Rofecoxib like 
compound had no effect on cytokine release. The results from the aforementioned studies reveal 
that willow bark appears to target mediators of the arachidonic acid pathway. Surprisingly, it was 
shown that willow bark processes less than a sixth of the amount of salicin. Therefore, it is logical 
to assume that the anti-inflammatory effects of willow bark must come from other constituents 
such as polyphenols, due to the observed superiority in decreasing oxidative stress in the form of 




2.2.3 Components of Willow Bark       
 Willow bark extract is accepted as both an analgesic and anti-rheumatic drug (Bonaterra 
et al., 2010; Vlachojannis et al., 2009). A common belief and misconception is that salicin or its 
metabolite salicylic acid is responsible for willow barks analgesic and anti-inflammation 
properties (Altinterim, 2013; Saller et al., 2008).Compared to aspirin, willow bark is shown to 
contain a low quantity of salicin that is metabolized into salicylic acid in the liver (Altinterim, 
2013). In fact, compared to others salix species, willow bark has the lower salicin concentration 
(Schmid et al., 2001). A single dose of willow bark containing 240mg of salicin produces a 
salicylate concentration equivalent to a low dose aspirin (100mg) (Vlachojannis et al., 2009). At 
the highest recommended dosage of salicin (240mg), it appears that this would correlate to more 
of a cardioprotective dose rather than an analgesic dose (Schmid et al., 2001).   
 Assuming willow bark had 100% bioavailability, a dosage of 240mg salicin would be 
converted to only 115mg of salicylic acid  (Schmid et al., 2001).This amount of salicylic acid is 
not large enough to produce any analgesic or anti-inflammatory effects (Oketch-Rabah et al., 
2019). Peak salicylic acid concentration is observed within two hours after consumption  (Schmid 
et al., 2001). Therefore, it seems logical to assume that the pharmacological activity must come 
from other sources. The anti-inflammatory and analgesic effect of willow bark may come from 
other compounds identified in willow bark such as polyphenols, derivatives of salicin, condensed 
tannins, and other compounds such as p-hydroxybenzoic, vanillic, cinnamic, p-coumaric, ferulic, 
caffeic acids and other phenolic acids (Altinterim, 2013; Drummond et al., 2013; Freischmidt et 
al., 2012; Harbourne et al., 2009; Oketch-Rabah et al., 2019). 
  The most popular belief among researchers is that the anti-inflammatory effects of willow 
bark is due to high levels of polyphenols (salicylates, flavonoids, proanthocyanidins, and tannins) 
and the different effects of these compounds on distinct targets (Oketch-Rabah et al., 2019). 
Several studies (Drummond et al., 2013; Freischmidt et al., 2011) have been done in vitro to bring 
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clarity on the role that polyphenols play in the anti-inflammatory effects of willow bark. 
Freischmidt et al (2011) tested the inhibitory effects of aqueous willow bark extract (STW 33-1) 
at 10μg/ml and 50μg/ml on tumor necrosis factor (TN-α) induced intercellular adhesion 
molecule-1 (ICAM-1) expression in endothelial cells. ICAM-1 is believed to play a role in the 
inflammatory process in endothelial cells by initiating the process of atherosclerosis. The results 
of this in vitro study showed STW 33-1 had a significant dose dependent reduction of ICAM-1 
compared to the control. The authors partitioned the aqueous willow bark to determine which 
polyphenols were responsible for the decrease in inflammation. Through a liquid/liquid partition 
protocol, it was discovered that the presence of catechol and flavanone aglycone eriodictyol 
where the only isolated polyphenols to show anti-inflammatory activity. The author’s concluded 
that in vitro, catechol, flavonoids and salicin derivatives contribute to the anti-inflammatory 
activity of willow bark.           
 Drummond et al., (2013) examined the effects of the aqueous willow bark extract (STW 
33-1), chamomile and meadowsweet and their isolated polyphenolic compounds (salicylic acid, 
apigenin, and quercetin respectively) on anti-inflammatory activity using IL-Iβ, IL-6 and TNF-α 
as the biomarkers of inflammation in a macrophage cell model at both high (50μL) and low 
(10μL) concentrations of the willow bark extract. The results revealed that 7.5g willow bark 
extract contained 7.74g/L of phenols and that the willow bark extract showed the greatest 
reduction of inflammatory mediated cytokine activity at both high and low concentrations of the 
extract. The isolation of the polyphenols revealed that salicylic acid induced the lowest anti-
inflammatory effects compared to apigenin and quercetin. The researchers concluded that 
polyphenols contributed to the anti-inflammatory and antioxidant properties of willow bark 
extract. The results from the aforementioned studies show, contrary to popular belief, willow bark 
extract is not a natural form of aspirin. The extend in which salicin and salicin derivates 
contribute to the anti-inflammatory and analgesic effects of willow bark appear to be minimal 
compared to polyphenols, flavonoids, and other compounds. 
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2.2.4 Recommended Dosage and Regulation 
To date, there is no uniform recommended dosage of willow bark extract. Currently, 
guidelines suggest an allowance ranging from 7.5 to 900mg of extract per day with no more than 
240mg of salicin (Oketch-Rabah et al., 2019). There are many different willow bark products on 
the market and there is disparity in the recommended dosage with doses ranging from less than 
100mg extract per day to over 800mg extract per day (Oketch-Rabah et al., 2019). The European 
Medicine Agency (EMA) recommends a daily dose of 393-1572mg extract corresponding to no 
more than 240mg salicin consumed for no more than four weeks at a time (European Medicines 
Agency, 2017). 
While the recommended intake is similar in both Europe and the United States, there is a 
distinct difference in the regulation and the recognition of willow bark extract for its 
pharmacological properties. For instance, in the United States, willow bark in not recognized by 
the U.S Food and Drug Administration (FDA), instead it is listed only as an old dietary ingredient 
in the United Natural Products Alliance (Oketch-Rabah et al., 2019). In Canada, willow bark is 
recognized as a natural health product. In Europe and Australia, there is more regulation on 
willow bark. In both countries it is recognized as herbal medicine with established use with 
scientific data supporting the recommended dosages and uses of the extract (Oketch-Rabah et al., 
2019). Currently, where willow bark is marketed as a dietary supplement, there is not a required 
label with safety guidelines regarding contraindications, pregnant women, or children. Like 
aspirin, pregnant women and those breastfeeding should avoid the consumption of willow bark 
due to the lack of literature investigating the effects on this population (Oketch-Rabah et al., 
2019). As stated earlier, willow bark contain salicylates, those allergic or sensitive to aspirin and 




2.3 Effectiveness of Willow Bark in Decreasing Pain 
 
2.3.1 Low Back Pain 
Low back pain is one of the most common musculoskeletal complaints worldwide 
(Gouveia et al., 2017) and is the leading cause of disability (Bhatia et al., 2020). Analgesics and 
NSAIDs are the standard treatment for low back pain with opioids being the most common 
prescribed medication (Bhatia et al., 2020; Gouveia et al., 2017; Shmagel et al., 2018) It is 
estimated that 1 in 5 Americans use opioids to treat their back pain (Bhatia et al., 2020; Gouveia 
et al., 2017; Shmagel et al., 2018). These medications, while effective in treating low back pain, 
are accompanied with risks such as addiction, gastrointestinal injury, hospitalization and even 
death. Recently, there has been an influx in research done on the effects of more natural remedies 
in the treatment of low back pain to decrease the potential adverse effects that are associated with 
the classic anti-inflammatory and analgesic medications. 
The efficacy and tolerability of willow bark has been studied in patients suffering from 
low back pain. Churbasik et al. (2000) examined the effects of a low dose (120mg) or a high dose 
(240mg) of salicin or placebo on chronic low back pain. In this randomized placebo controlled 
study participants took either the low (n =70) or high dose (n =70) willow bark extract or placebo 
(n =70) for four weeks. During this time, participants were allowed up to 400mg of tramadol 
daily as a rescue medication. The outcome measures for this investigation were the proportion of 
participants pain free for at least five days during the last week of the study, the proportion of 
patients who needed tramadol, and the change in the modified version of the Arhus Low Back 
Pain Index. Once a week, the researchers called the participants and asked about their level of 
pain, dose of tramadol consumed and if they had any adverse events that week. The results 
showed that 21% of participants in the low dose willow bark, 39% participants in the high dose 
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willow bark, and 6% participants in the placebo group were pain free and not taking tramadol at 
the end of the study. In addition, significantly (p < 0.05) more participants in the high dose 
willow bark group saw pain relief after one week of treatment. In the low dose willow bark 
group, participants experienced significantly (p < 0.05) more pain relief after the second week of 
treatment compared to the placebo group. Overall, significantly (p < 0.05) more participants 
needed tramadol in the placebo group compared to both willow bark extract groups. In this study, 
the researchers observed a dose-dependent effect regarding pain relief in participants who suffer 
from low back pain. The researchers concluded that willow bark may be an effective alternative 
to NSAIDs in those with back pain and cannot tolerate NSAIDs. 
Chrubasik et al. (2001a) conducted a four-week, open, non-randomized investigation on 
the economic effect of willow bark extract (Assalix) on the treatment of acute exacerbations of 
chronic non-specific back pain. There were 439 participants that completed the study with group 
one (n=115) receiving two capsules of Assalix per day (approximately 120mg salicin per day), 
group two (n = 112) received four capsules of Assalix per day (approximately 240 mg salicin per 
day) and group three (n = 224) received other conventional treatments that their doctors deemed 
appropriate. All groups were able to take part in other conventional treatments (nerve block, 
acupuncture, or transcutaneous electrical nerve stimulation) and could consume NSAIDs as 
needed. The modified Arhus Index (Chrubasik et al., 1996) to assess pain, disability, and physical 
impairment and the Total Pain Index 9 Chrubasik et al. (2000) to measure pain while sitting, 
lying, upright, moving, and at night were measured at the beginning and end of the study. In 
addition, after the first and second week of treatment, the patients were contacted by the 
researcher to evaluate their overall well-being, occurrence of adverse effects, and to document 
any changes in the treatment of their back pain. At the end of the study, 16% of participants in 
group one, 30% in group two and 17% in group three were pain free. A dose dependent effect on 
the patients belief of treatment success, feelings of well-being and the proportions of patients who 
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did not need additional treatment was observed. It was found that 73% of participants in group 
two (240mg salicin) believed the treatment was successful while group one (120mg salicin) and 
placebo had similar responses to treatment success (63% and 64% respectively). In patients 
receiving the high dose of willow bark extract, only 30% needed additional treatments compared 
to 45% in the low dose extract group. In addition, less than 25% of the patients receiving Assalx 
used additional NSAIDs during the four-week treatment period. Regarding cost effectiveness, 
those receiving Assalx spent 14-50% less money during the four-week period on treatment 
compared to group three who receive traditional care for low back pain without Asslax. Based on 
the results this study, the authors concluded the cost of treating low back pain could be lowered 
by including willow bark extract into the treatment regimen. Due to the absence of randomization 
in the study and that patients could continue with other treatment regimens, any effectiveness of 
Asslax in decreasing low back pain cannot be confidently contributed to Asslax alone.  
A third study by Chrubasik and colleagues (2001b) compared the effects of willow bark 
extract (Assalix) and Rofecoxib (selective COX-2 inhibitor) on low back pain in an open 
randomized study with 228 participants with non-specific low back pain lasting at least six 
months taking part the four-week study. Participants were randomly placed in the Assalix group 
(n = 114) where they consumed four capsules per day which was equivalent to 240mg of salicin 
or the Rofecoxib group (n= 114) who consumed a single 12.5mg tablet daily. The participants 
were instructed to continue with their other medications, NSAIDs and other conventional 
treatments (massage, physical therapy etc.). The outcome measurements, perceived pain on a 
VAS, the Modified Arhus Index(Chrubasik et al., 1996), and the Total Pain Index (Chrubasik et., 
al 2000) were measured at baseline and once again at the end of the study. The results showed 
that both groups had similar treatment effects. Combining the groups together, the pain 
component on the Arhus Index improved by 30%, Total Pain Index improved 35% and the 
modified Arhus Index improved by 20%. In each group, 20 participants were completely pain 
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free following the four-week treatment period. Regardless of grouping, 21 participants required 
additional treatment. In the Assaix group, the additional pharmacological treatment for pain relief 
was equivalent to 120mg Diclofenac and 5mg tramadol over the four weeks. In comparison, the 
Rofecoxib group on average required less NSAIDs (42mg Diclofenac equivalent) but more 
tramadol (17mg) over the course of the study. Based on the results of the study, the researchers 
concluded that Assalix is just as effective as Rofecoxib in treating low back pain. 
 
2.3.2 Arthritic Conditions 
Arthritis consists of a variety of conditions such as osteoarthritis, gout, rheumatoid 
arthritis, or coxarthrosis. Between the years of 2013-2015 in the United States, 54.4 million 
Americans were diagnosed with arthritis and required treatment (Barbour et al., 2017). The use of 
NSAIDs is often long-term in the management of symptoms and in treatment of pain (Crofford, 
2013). The long-term use of NSAIDs often lead to adverse events that can lead to hospitalization 
or death. Therefore, scientists and researchers have been searching for a more homeopathic 
treatment for these conditions and one of the potential alternative treatments is the extract from 
the willow bark tree. 
  Biegert, et al (2004) conducted a six-week, three arm, randomized controlled study to 
compare the efficacy of willow bark to Diclofenac and a placebo. To be eligible to participate, 
participants had to be diagnosed with osteoarthritis in either the hip or knee and not had 
corticosteroids or surgery involving the effected joints eight weeks prior to the start of the study. 
The study consisted of an osteoarthritis and rheumatoid arthritis trial in which 127 outpatients 
with hip or knee osteoarthritis and 26 outpatients with active rheumatoid arthritis took part in this 
study. In both trials, a washout period lasting 4-10 days (depending on the half-life of the 
analgesic or NSAIDs) took place before the start of the study. For the osteoarthritis trail, the 
26 
 
participants were randomly placed in one of the three conditions (willow bark extract, Diclofenac 
or placebo). The willow bark dosage was two tablets, two times daily for a total of 240mg of 
salicin per day. The Diclofenac group took two tablets, twice daily resulting in a total of 10mg 
per day while the placebo took two sugar tablets daily. Each participant took their medication for 
six weeks, 30 minutes before meals in the morning and afternoon. During the study period, the 
participants were allowed up to 100mg of aspirin per day if needed for pain and inflammation. 
The participants were assessed by a physician on day -7, 0, 14 and 42 and the participants 
completed a questionnaire on day 28 on the efficiency on the medication. Pain was addressed by 
the Western Ontario McMaster University Osteoarthritis Index (WOMAC), safety of drug (blood 
and urine samples), and the participants assessment of tolerability on a 100mm visual analog 
scale (VAS) and a perceived quality of life on short form -36 (SF-36) on day 0 and day 42. After 
six weeks of treatment, the results showed that all groups had improved. Regarding the WOMAC 
pain score, the Diclofenac group had a significant (p < 0.05) pain reduction (23mm) while the 
willow bark and placebo had similar improvements in pain (8mm and 5mm respectively). In 
addition, the Diclofenac group had significant (p < 0.05) improvements over the placebo 
regarding joint stiffness, body pain, physical function, and physical role. Once again, the willow 
bark extract group had comparable results to that of the placebo in all variables except for 
physical function. Both the patients and treating physicians agreed that the Diclofenac resulted in 
strong improvements while the willow bark extract resulted in minimal improvements compared 
to the placebo.  
  In the rheumatoid arthritis trail, participants were randomly placed in either the placebo 
(n = 13) or willow bark extract (n =13) condition. While the dosage of the willow bark extract 
was the same as the osteoarthritis trial, the participants were allowed no more than 7.5mg of 
corticosteroids and no more than 100mg of aspirin per day to control pain and inflammation. The 
same study designed was carried out in this trial as it did for the osteoarthritis trial. The results 
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from the rheumatoid trial showed that at baseline the willow bark extract group had a more active 
disease state compared to the placebo. While not statistically significant (p > 0.05) after six 
weeks, willow bark extract decreased pain greater than the placebo (15% and 4% respectively). 
Secondary outcomes such as number of painful, tender, or swollen joints, disability index, and 
severity of morning stiffness was not significantly different than placebo. The authors concluded 
that they found no evidence that willow bark extract exhibits any analgesic or anti-inflammatory 
effects in those with osteoarthritis or rheumatoid arthritis. Based on the results, it is speculated 
that the dose of willow back used (240mg salicin) was not large enough to have any success the 
treatment of osteoarthritis or rheumatoid arthritis. 
Saller, Melzer, and Felder (2008) conducted a 6-8 week observational study with a 
control visit after week three and four on the effectiveness of willow bark extract (Assalix) 
relieving pain in patients with rheumatic pain in the neck or back. In total, 204 physicians treating 
763 patients with rheumatic pain participated in the study. The variables of interest were pain, 
intensity of pain, impairments of daily activities, and a global assessment of efficacy and 
tolerability. Pain was assessed on a 0-9 scale and following treatment with Assalix had decreased 
by 2.81± 2.11 points (pre: 5.32±1.62; post: 2.51± 2.04). In fact, 14% of the patients were 
completely pain free after 30. 01 ± 18.86 days of treatment. In addition, at the start of treatment 
only 0.6% of patients stated they had no impairments of daily activities, Remarkably, at the end 
of the study, 27.4% stated they had not impairment of daily activities. The global assessment 
revealed that 65.8% of patients believed that the willow bark extract was effective in treating their 
pain and 62% of the patients continued with Assalix after the completion of the study. The 
authors discovered a dose-dependent response in terms of pain reduction. A higher dose (3-4 
tablets per day) was slightly more effective than the recommended dose of 1-2 tablets per day. 
While researchers believed that willow bark extract is well tolerated and offers a moderate 
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analgesic effect, the results should be regarded with caution because there was not a placebo nor a 
control group. 
Schmidt et al (2001) assessed the efficacy of willow bark in a two-week double-blind 
randomized controlled study in patients with a confirmed diagnosis of knee or hip osteoarthritis. 
The participants were randomly placed into the placebo or willow bark extract group (two tablets 
twice a day, corresponding to 240mg salicin per day). Both groups took their medications 30 
minutes before meals in both the morning and noon. After a 2-4 day washout with a placebo, the 
participants were treated with either willow bark extract or placebo. Participants were assessed by 
a physician on days -4, 0, 7, and 14 of the study. Participants rated their physical function and 
pain on a 100mm VAS every evening. On days 7 and 14 the participants filled out the WOMAC 
questionnaire that assessed pain, stiffness, and physical function. Compliance and adverse events 
were checked with a tablet count and diary entries, respectively. At the end of the two week 
treatment period, there was a significant difference between the placebo and willow bark extract 
groups in the WOMAC pain dimension (d= 6.5mm, p = 0.047). The WOMAC pain score was 
14% lower in the willow bark extract group in comparison to the placebo group which had a 2% 
increase in pain. Physical function and stiffness improved more in the willow bark extract group, 
but the change was not statistically significant (p > 0.05) compared to the placebo group. Lastly, 
there was a significant improvement in disease state in the willow bark extract group reported by 
both physicians (p = 0.0073) and participants (p = .0002). 
Beer and Wegener (2008) conducted an open observational study on adults from the ages 
of 50-75 years old with coxarthrosis with hip pain or gonarthosis with knee pain. The participants 
had to meet at least two of the three criteria of pain at night, morning stiffness, pain lasting for at 
least 30 minutes following the initiation of movement. The participants consumed dry willow 
bark extract (393.24mg) tablets that could be taken up to two times daily with salicin content 
ranging from 120-240mg. The study lasted six weeks with a physician examination at week three 
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and six. To gauge effectiveness, the treating physician assessed tenderness of joints, restriction of 
movement, crepitation, swollen joints, and the severity of disease according to the Clinical Global 
Impression (CGI) five-point scale. In addition, participants rated their perceived effectiveness of 
treatment and the WOMAC questionnaire that assessed pain, stiffness, and physical function on 
week three and six. Lastly, tolerance was recorded after week three and six in the form of adverse 
effects reported by both participant and physician. Nine doctors and 139 patients participated in 
the study with 88 participants in the willow bark extract group, eight in the combination (willow 
bark extract + NSAIDs) group and 40 in the reference medication (NSAIDs only) group. The 
results showed that all groups saw improvements in symptoms after three weeks of treatment and 
greater improvements by the end of the study. On average, the reference group saw improvements 
in 8.49 days. while the willow bark extract group saw improvements in 13.52 days. After six 
weeks, there was a trend towards the willow bark extract bring more effective in decreasing pain 
depicted by the WOMAC score (willow bark extract -41.8%; reference medication: -32.4%) and 
stiffness (willow bark extract: -42.1; reference medication; -30.9%). In terms of effectiveness, 
treating physicians stated that the reference medication had a stronger and faster reaction after 
three weeks of treatment but after six weeks of treatment, the reference group was only slightly 
more effective in treating gonarthosis and coxarthrosis. Most of the patients (92.2%) in the 
willow bark extract group consumed the maximal dosage allowed (1.572g of extract with 240mg 
salicin) to combat pain and inflammation. The researchers concluded that willow bark extract, at 
the highest dose allowed, is comparable to NSAIDs in treating inflammation associated with 
nociceptor pain. 
Uehleke and colleagues (2013) examined the effects of aqueous willow bark extract 
(STW 33-I) in the long term (>6 months) treatment of musculoskeletal disorders such as 
osteoarthritis or back pain. During this 24 week study there was no strict drug regimen. 
Participates could take STW 33-I (with 23-26% total salicin) alone or with other NSAIDs or 
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analgesic medication. Measurements were obtained at baseline and after 3,6,12,18, and 24 weeks. 
Primary measurements were a global pain assessed on a 0-100mm VAS, efficacy of treatment 
measured by the treating physician, safety, and tolerability of the willow bark extract. The 
patients were required to keep a daily diary where they self-rated their pain, documented any 
changes in pain or therapy and the dosage of STW 33-I and other medication consumed during 
the 24 weeks. In total, 436 participants with 58% having either osteoarthritis or back pain for at 
least five years participated in the study. At the beginning of the study all participants were taking 
the willow bark extract. By the end of the 24 weeks, 61.5% of the patients took no analgesic co-
medication, 28.9% took NSAIDs, and 3.9% required a triple therapy of STW 33-I, NSAIDs and 
opioids. During the treatment period, patients experienced a significant (p < 0.05) and continuous 
pain relief. After three weeks of treatment, a clinically relevant pain reduction was observed with 
pain 45.6% lower than what it was at baseline. Remarkably, after 24 weeks of treatment, 
regarding symptoms, 60% of patients were completely or partly in remission. Based on the 
results, the authors concluded that willow bark extract had a mild effect as an analgesic and those 
suffering from mild or chronic pain could be treated with willow bark extract alone. They also 
suggested that physicians should consider starting a treatment regimen with willow bark extract 
alone and adding NSAIDs or opioids as needed.  
 
2.3.3 Summary of “Effectiveness of Willow Bark in Decreasing Pain” 
Willow bark may be a potential natural remedy for gonarthosis, coxarthrosis and other 
musculoskeletal disorders that result in pain. The consensus among researchers is that willow 
bark is either more effective (Beer & Wegener, 2008; Saller et al., 2008; Schmid et al., 2001) or 
just as effective (Chrubasik, Künzel, Model, et al., 2001; Uehleke et al., 2013) in decreasing pain 
compared to other NSAIDs or placebo. In contrast, (Biegert et al., 2004) concluded that the 
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standardized NSAID used to treat osteoarthritis, diclofenac, was more effective than willow bark 
in decreasing pain and increasing physical function. In addition, they found that willow bark was 
no more effective than a placebo pill in the treatment of pain. In the treatment of low back pain, 
rheumatoid pain, and other musculoskeletal disorders there is a trend of a dose dependent 
response (Beer & Wegener, 2008; Sigrun Chrubasik et al., 2000; Saller et al., 2008) in the 
alleviation of pain with 240mg of salicin being more effective than 120mg.  
Due to the more observational nature most of these studies (Beer & Wegener, 2008; 
Chrubasik, Künzel, Black, et al., 2001; Saller et al., 2008; Uehleke et al., 2013) caution should be 
warranted with interpreting the results as most studies allowed the participants to continue taking 
NSAIDs with willow bark. Therefore, it is difficult to determine if the pain relief was due to 
willow bark alone or from the combination of willow bark with NSAIDs or opioids. More 
randomized, placebo-controlled studies should be done to confirm the effectiveness of willow 
bark on the alleviation of pain in those suffering from musculoskeletal disorders. 
 
2.4 Adverse Events Associated with Willow Bark Compared to other NSAIDs  
 
2.4.1 Willow Bark and Platelet Aggregation  
Aspirin and other NSAIDS have a higher risk of adverse effects such as gastric ulcers, an 
increased risk of bleeding and gastrointestinal upset that is rarely observed with the consumption 
of standardized willow bark extract (Bonaterra et al, 2010). The long-term consumption of aspirin 
increases the risk of gastrointestinal bleeding and other bleeding disorders. Aspirin, when it 
blocks COX-1, inhibits the synthesis of platelet thromboxane A2 irreversibly impending the 
substrates access to its active site. (Catella-Lawson et al., 2001; Sostres & Lanas, 2011). Since 
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thromboxane A2 is required for the synthesis of new platelets, the consumption of aspirin inhibits 
platelet formation for the duration of the platelets 8-10 day lifespan (Cryer, 2010). The inhibition 
of platelet aggregation increases the chances of developing bleeding disorder. In addition, by 
preventing platelet aggregation, aspirin can enhance the bleeding potential in those who have 
asymptomatic gastrointestinal mucosal lesions (Vlachojannis et al., 2009). In comparison, 
naturally occurring salicylic acid does not function as an anticoagulant and does not inhibit 
platelet aggregation. Consuming willow bark instead of aspirin may decrease the risk of 
experiencing a bleeding disorder. In addition, willow bark may be able to be continued leading up 
to a surgical procedure unlike aspirin which is often stopped 7-14 days prior to the procedure. 
However, more research needs to be done to confirm this theory. 
 
2.4.2 Reported Adverse Effects with Willow Bark 
Compared to aspirin, willow bark is believed to have a lower toxicity due to its low level 
of salicylates (Vlachojannis et al., 2009). However, the data on willow back’s toxicity is lacking 
in the literature (Catella-Lawson et al., 2001). According to the Food and Drug Administration 
(2003), willow bark is shown to be consumed for over three months without any adverse effects. 
In all the clinical trials published, only 5% of all participants had some sort of adverse effect from 
the consumption of willow bark and those reactions were mild (Anonymous, 2003). It appears 
that willow bark has a low incidence of adverse effects compared to aspirin due to the addition of 
other constitutes and the absences of acetylsalicylic acid. The co-active compounds (salicylates, 
flavonoids, catechol, and tannins) are not known to be harmful to the gastrointestinal mucosa 
compared to acetylsalicylic acid (Nikose et al., 2015). As of date, there is only one account of an 
individual experiencing anaphylaxis following the ingestion of a weight loss supplement 
containing willow bark. The female patient had a known allergy to acetylsalicylic acid and after 
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the administration of epinephrine, diphenhydramine, methylprednisolone, and volume 
resuscitation she recovered from the reaction (Boullata et al., 2003). 
Many of the studies that examined the effectiveness of willow bark in treating conditions 
that resulted in pain and inflammation had a secondary analysis on the safety and tolerability of 
willow bark compared to a placebo or traditional NSAIDs. In the investigation done by Biegert 
and colleagues (2004) on efficacy and safety of willow bark in treating those with either 
osteoarthritis or rheumatoid arthritis, the authors reported 173 adverse effects in the osteoarthritis 
trial with most occurring in the Diclofenac group (n =84) compared to the placebo (n= 51) and 
willow bark (n = 38) groups. There were significantly (p < 0.05) 0more gastrointestinal adverse 
effects in the diclofenac group (n= 35) compared to the willow bark group (n= 7). After six weeks 
of consuming 100mg of diclofenac daily, the liver enzymes alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT)had significantly 
increased. The increase in liver enzymes following Diclofenac consumption is a common 
occurrence due to the liver playing a role in the removal of this drug from the body (Nikose et al., 
2015). In the rheumatoid trial both groups reported seven adverse events each with none of them 
being classified as serious.  
Chrubasik et al (2000) examined the effects of a low dose (120mg salicin), a high dose 
(240mg salicin) or placebo on its ability to decrease low back pain. In this four-week 
investigation, participants could use tramadol up to 400mg per day as a rescue medication. Out of 
the 191 participants who completed this study, only nine participants reported an adverse event. 
In the high dose willow bark group two participants experienced dizziness or fatigue which were 
later linked back to the tramadol. In the low dose willow bark group, one participant experienced 
swollen eyes and pruritus that improved once willow bark was discontinued. In the placebo 
group, six participants experienced adverse events with three be contributed to the tramadol. 
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In a follow up study done by Chrubasik et al (2001a) on the economic effect of willow 
bark extract (Assalix) on the treatment of acute exacerbations of chronic non-specific back pain, 
the authors found that three causes of adverse skin reactions (exanthema and pruritus) were linked 
to the willow bark extract. In addition, 16 gastrointestinal complaints were documented with two 
complaints in participants receiving Assalix alone, four complaints in those receiving both 
Assalix and additional treatment and 10 in the group that received NSAIDs alone or cortisone 
treatment. A third study by Chrubasik and colleagues (2001b) compared the effects of willow 
bark extract (Assalix) and Rofecoxib (selective COX-2 inhibitor) on low back pain. After the four 
week treatment period, 23 adverse events occurred in the Assalix group and 27 in the Rofecoxib 
group. When the adverse events were broken down, 30 of those occurred within the 
gastrointestinal system (Assalix; n = 13; Rofecoxib: n = 17) with those in the Rofecoxib group 
being more severe in nature. In addition, there were five reports of a skin reactions in the Assalix 
group.   
In an open observational study on the effectiveness of willow bark extract (Assalix) 
decreasing pain in participants with rheumatic pain, Saller, Melzer, and Felder (2008) found that 
38 (4.3%) of the 204 participants reported 46 adverse events during the 6-8 week study. 
Predominantly of the adverse events occurred in the gastrointestinal system (3.1%), and the skin 
(1%). While none of the adverse events were severe, 30 participants discontinued with treatment. 
When the researchers cross examined the reported adverse events they found that 27 of the cases 
were likely caused by the treatment. In another open observational study conducted by Beer and 
Wegener (2008) on adults with coxarthrosis with hip pain or gonarthosis with knee pain, 14 of the 
139 participants documented adverse events. When cross examined, only one adverse event was 
reported in the willow bark group, 11 were reported in the reference medication group (NSAID 
only) and two in the combination group (willow bark extract + NSAID). The type of adverse 
events experienced by the participants were not disclosed by the researchers. Both treating 
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physicians and participants considered willow bark to be superior in tolerability compared to the 
reference medication.          
 Uehleke et al (2013) examined the effectiveness of aqueous willow bark extract (STW 
33-I) in the long term (>6 months) treatment of pain in those with osteoarthritis or back pain. This 
was one of the first studies to examine the tolerability of consuming willow bark on a long-term 
basis. The researchers evaluated the number of reported adverse events during the 24-week study. 
The researchers discovered that 176 adverse events were reported in 106 patients with 7 patients 
reporting a severe adverse effect. With further evaluation, the researchers concluded that none of 
the adverse events were related to the willow bark. When broken down into the treatment groups, 
35.8% of the adverse events occurred in the willow bark monotherapy group, 54.5% occurred in 
the combination group (willow bark + NSAIDs) and 9.7% in the triple treatment group (willow 
bark + NSAIDs + opioids). The most reported adverse effects occurred in the gastrointestinal 
system such as upper abdominal pain or nausea. Overall, the researchers concluded that willow 
bark extract is safe for patients to take on a long term basis (> 6 months) as a monotherapy and 
combination with other NSAIDs or opioids in the treatment of musculoskeletal disorders.  
Schmidt et al (2001) had participants with a confirmed diagnosis of knee or hip 
osteoarthritis consume a high dose of willow bark extract (240mg salicin per day) or placebo in a 
two-week double-blind randomized controlled study. During the investigation, participants were 
instructed to record any adverse events in their diary. At the end of the two-week treatment 
period, 16 participants (41%) in each group reported an adverse event. The most reported adverse 
effects were allergic skin reactions or gastrointestinal upset. Surprisingly, there were more 
reported adverse events in the placebo (n = 28) compared to that of the willow bark group (n = 
17). Only one reaction was considered as clinical importance in the willow bark group in which 
the participant developed a skin rash near the end of the study and dropped out the of 
investigation. The participant had a medical history of reacting to various medications.  
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Akao and associates (2002) conducted an in vivo study in which they compared the 
effects of salicin, saligenin, sodium alicylate, and pure water on gastrointestinal lesions in rats. 
The compounds were orally administered at a dose of 1, 2.5 and 5m/mol/kg body weight. When 
examining lesions, the authors found the oral administration of up to 5mmol/kg of sodium 
salicylate and saligenin promoted the development of injuries to the mucosa of the stomach such 
as bleeding, serious wounds, and gastric lesions. A higher dose of sodium salicylate consumed 
resulted in greater gastric injury. In comparison, salicin, regardless of dosage, did not produce any 
indications of a gastric injury. In the rats that consumed salicin, the degree of injury was 
comparable to that of rats who received just water. It was concluded that salicin from willow bark 
could be an alternative medication used to treat musculoskeletal conditions in individuals with a 
history of developing gastric lesions from consuming aspirin or other NSAIDs. 
 
2.4.3 Conclusion of Willow Barks Adverse Effects 
Based on the review of literature, it can be concluded that willow bark extract may be 
tolerated better with less gastrointestinal effect than NSAIDs or aspirin due to the low levels of 
salicin and abundance of polyphenols and flavonoids which target inflammatory mediators in a 
different manner. Compared to NSAIDs, the adverse effects appear to be mild with the most 
common reported being minor gastrointestinal upset. Due to apparent low toxicity, many 
physicians in Europe often recommend the use of willow bark in conjunction with aspirin to 
enhance the treatment effects in hopes of decreasing the risk of adverse reactions (Altinterim, 
2013). It is important to note that most of the investigations allowed the participants to continue 
with their normal use of NSAIDs or allowed the use of opioids as a recue medication while taking 
willow bark extract. Therefore, the exact number and degree of adverse effects due to willow 









A double-blind randomized placebo-controlled study design was utilized to determine the 
effects of white willow bark (WWB) on parameters of delayed onset muscle soreness (DOMS) 
and if WWB could maintain athletic performance following an exhaustive lower body resistance 
training session. To investigate the effects of WWB on DOMS and athletic performance, 
participants completed an exhaustive lower body resistance training session to induce DOMS 
followed by a five day supplementation period in which the participants ingested either WWB or 
a placebo. Prior to inducing DOMS, baseline data for parameters of DOMS and athletic 
performance was collected and tracked the changes of these variables over the course of DOMS 
development and recovery. Statistical analysis was completed to compare the means between the 
WWB and placebo group to determine the effect of WWB on parameters of DOMS and its ability 
to maintain athletic performance. This investigation was approved by the Oklahoma State 






3.2 Participants  
Twenty-five participants volunteered for this investigation. All participants were required 
to be healthy and free from any signs or symptoms of disease, without any musculoskeletal 
injury, previous surgery within the last six months involving the hip, low back, knee, or ankle. In 
addition, had to be free from any type of arthritis (i.e., osteoarthritis, gout, rheumatoid arthritis) or 
have chronic back pain. The participants could not be participating in a lower body resistance 
training program on a regular basis (at least 3 days a week for the last 3 months). During this 
investigation, participants were required to refrain from participating in any exercise or physical 
activity program involving the lower body. Furthermore, participants were asked to refrain from 
taking any NSAIDs, analgesics, corticosteroids, or any type of nutritional aid that could interfere 
with the potential therapeutic actions of WWB. Those who were taking medication known to 
interfere with WWB (i.e., anticoagulants, beta blockers, diuretic, methotrexate, or phenytoin) and 
those with a known allergy or sensitivity to salicylates such as aspirin were excluded from this 
investigation. Following enlisting the participants, their first visit to the Applied Neuromuscular 
Lab was scheduled. During the first visit, participants completed a health history questionnaire 
(Appendix A) to verify they met the inclusion criteria for this investigation. Then the researcher 
and participant discussed the IRB informed consent form and the requirements of the study and 
the participant expectations. Afterwards, the participants completed a familiarization four 
repeated counter-movement jump session and became familiar with the visual analog scale (VAS) 
(Appendix B). Following the completion of session one, each participant was randomly place in 
either the WWB group (n= 11) or placebo group (n = 14).  
3.3 Study Design 
The current investigation included four visits to the Neuromuscular Physiology Lab and 
five days of supplementation as outlined in Figure 3. Session one consisted of equipment 
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familiarization, height, weight, and the competition of pre-participation paperwork. After session 
one, participants were randomly assigned one of the treatment groups. During session two, 
baseline measurements parameters of DOMS (muscle soreness, mid-thigh circumference, and 
pressure pain threshold) were  measured. In addition, baseline athletic performance was measured 
with a four repeated counter-movement jump test in which jump height, ground-contact time and 
peak power and peak velocity was recorded. After the collection of baseline data, participants 
took part in a lower body resistance training session to induce DOMS. After the completion of the 
training session and resting for 10 minutes, the parameters of DOMS were measured again 
followed by the four repeated counter-movement jump test to measure the immediate response to 
muscle fatigue. Participants were provided with a brown container that held their first dose and 
additional five day supply of WWB supplement or placebo and given instructions for ingesting 
their randomly assigned treatment. Participants ingested their first dose (two capsules) of either 
WWB or placebo with water and were instructed to not take another dosage until the next 
morning. Beginning the morning after session two, participants began the five day 
supplementation period. Participants were asked to take two capsules of their assigned treatment 
morning, noon, and night with food. Each morning during the supplementation period 
participants rated their muscle soreness within 30 minutes of waking. Participants were required 
to report back to the Neuromuscular Physiology lab on day three (72 hrs.) and day 6 (post) a 
repeated measurement of parameters of DOMS and athletic performance. All testing procedures 





3.4 Instruments and Procedures 
 
3.4.1 Height and Weight 
During the first visit to the Neuromuscular Physiology Lab, weight, and height were 
measured. Weight was measured on a floor scale (CPW Plus 150; Adam Equipment™, Oxford, 
CT, USA) and height was measured with a height beam on a physician scale (Weight-Beam Eye-
Level physician Scale; Detecto, Webb City, MO, USA). For this investigation, the participant’s 
weight was used to calculate the percentage of body weighted the used during the exhaustive 
lower body resistance training session to induce DOMS. 
 
3.4.2 Visual Analog Scale 




A visual analog scale (VAS) consists of a 100mm line with polar extremes (none and 
extreme) to assess pain. This subjective scale has been used in many various studies and is 
considered a valid and reliable way to assess pain and soreness (Hoseinzadeh et al., 2015; Pumpa 
et al., 2013; Wheeler & Jacobson, 2013). The baseline VAS was measured during session two 
before participants completed the lower body resistance training session to induce DOMS. 
Participants were asked to rate their level of pain or discomfort for their quadriceps, hamstrings, 
gastrocnemius, and gluteal muscles. Each participant was sent home with a five day VAS packet 
with instructions. Each day during the supplementation period, participants rated their level of 
pain or discomfort for the quadriceps, hamstrings, gastrocnemius, and gluteal muscles each 
morning within 30 minutes of waking. On day six (session four), participants brought their VAS 
packet to their last session to turn in to their primary investigator for analysis and they completed 
their final (post supplementation) VAS. 
 
3.4.3 Mid-Thigh Circumference 
Participants were asked to place one foot on a chair, so both the knee and hip were at 90° 
measured by a goniometer. Using a Gulick tape measure, the midpoint between the inguinal 
crease and the proximal border of the patella was measured. Using a semi-permanent marker, a 
small dot was placed at the midpoint where mid-thigh circumference was to be measured. With 
the zero of the Gulick tape measure placed on the small dot, thigh circumference was measured to 
the nearest 0.1cm and recorded. Three measurements were obtained, and the average was 
recorded. This was completed for both right and left mid-thigh. Mid-thigh circumference was 
measured at baseline, immediately following exercise, day three (72hrs.) and day six (post). 
 
3.4.4 Pressure Pain Threshold 
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A handheld algometer (Wagner Force Ten TM Digital Force Gage; Wagner Instruments, 
Greenwich, CT, USA) was used to measure pressure pain threshold. A handheld algometer has 
been shown to be a valid and reliable tool in evaluating pressure pain threshold (Kinser et al., 
2009; Waller et al., 2015). Participants were asked to sit in a chair with feet flat on the ground and 
knees at 90° measured with a goniometer. Using the same spot where mid-thigh circumference 
was measured (the midpoint between the inguinal crease and the proximal border of the patella) 
the handheld algometer was placed on the dot. Participants were asked to report when “pressure 
started to feel uncomfortable.” Pressure was applied in a slow downward manner and at the 
participants response of “stop” the measurement was recorded to the nearest 0.01oz. The average 
of three measurements were obtained for both right and left mid-thighs while alternating thighs 
after each measurement. Pressure pain threshold was measured at baseline, immediate response, 
day three (72 hrs.) and day six (post). 
 
3.4.5 Four Repeated Countermovement Jumps 
A four repeated countermovement jump test was used to determine the detrimental 
effects of DOMS on performance and if WWB could maintain athletic performance. Participants 
wrapped the Tendo Unit (Tendo Sports, Trencin, Slovak Republic) strap around their waist. The 
Tendo Unit measured both peak power and peak velocity during the four repeated 
countermovement jumps. When instructed, participants stepped on the switch mat (Just Jump; Pro 
Biotics Inc, Huntsville, AL, USA). The participants were asked to stand upright on the mat with 
the weight distributed on both feet with their hands on their hips. When ready, participants 
squatted to approximately 90° and immediately jumped vertically as high as possible landing 
back on the mat with both feet at the same time. Immediately after their feet landed on the mat 
they jumped vertically as high as possible once again. The participants completed four 
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countermovement jumps in a row with their hands always remaining on their hips. The average 
ground contact time and the average vertical jump height were recorded. The average vertical 
jump height was converted to metric units (centimeters) before data analysis. The participants 
completed this test at baseline, immediate response, day three (72hrs.) and day six (post). 
 
3.4.6 Fatiguing Protocol          
Following the collection of baseline data, participants took part in a lower body resistance 
training session to induce DOMS. After a five minute warm up on a cycle ergometer, participants 
first performed five sets of 10 lunges at 40% of their body weight (BW) with a one minute rest 
between sets. Participants performed lunges with alternating legs. Participants stood straight with 
a dumbbell in each hand (20% BW right and 20% BW left) with their feet shoulder width apart. 
When ready, the participant took a large step forward so the thigh of the lead foot was located 
directly above or slightly in from the toes with the opposite knee slightly behind the hips and 
slightly bent (about one inch above the level the floor). Using the power of the lead leg, the 
participant pushed backwards so that both feet were together again. These steps were repeated 
with the opposite leg until all sets and repetitions were completed. Following the completion of 
lunges, the participant completed three sets to fatigue on the seated leg press (Hammer Strength 
Select Seated Leg Press; Life Fitness Inc, Park, IL, USA) at 75% of their body weight with a one 
minute rest between each set. To standardize the protocol during the leg press, a metronome 
(Metronome app by ONYX Apps; Apple Inc, Cupertino, CA) was set at 60 beats per minute 
(Selkow et al., 2015). Fatigue was determined when participants could no longer lift the weight or 
could no longer keep up with the metronome on three consecutive counts. 
 
3.4.7 Treatment Conditions 
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Participants were randomly assigned to either the WWB or placebo group using a 
computerized randomized scheme. WWB was purchased from the company Puritan’s Pride. 
Immediately following the collection of the immediate response data, participants were handed a 
brown container that held a sandwich bag with their supplements and instructions on how to take 
their supplement. Giving participants a brown container kept the researcher from knowing which 
group the participant was placed in. Once the participants received their container, they ingested 
their first dose (two capsules) of WWB or placebo with water. Beginning the morning after 
session two, participants began the five day supplementation period. During the supplementation 
period, participants in the WWB group took two capsules containing 133mg of willow bark 
extract three times daily for a total of 798mg per day. The placebo group took two capsules 
containing powder sugar three times daily. Participants in both treatment conditions were 
instructed to ingest two capsules in the morning, noon, and evening with food to decrease the risk 
of adverse effects. Each morning during the supplementation period, participants received a text 
message reminding them to take their supplement and to fill out their VAS. On the last session 
(day six), participants were required to bring back container that contained the supplement for a 
compliance check. A compliance of 80% was set for data to be included in the statistical analysis. 
This percentage was used in a previous that examined the effects of a natural supplement on 
DOMS (Jäger et al., 2019). 
 
3.4.8 Statistical Analysis 
Prior to analysis, box and whisker plots were used to determine and eliminate any outliers 
and the data was checked for normality with the Shapiro-Wilks test. Levene’s test was performed 
to evaluate the homogeneity of variances. Furthermore, Mauchley’s test was applied to evaluate 
the assumption of sphericity for repeated measures ANOVA. If the assumption was sphericity 
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was violated, the Greenhouse-Geisser was used. Statistical analysis was performed using SPSS 
statistical software (Version 27.0, IBM Corp, Chicago, IL, USA). Twelve two-way repeated 
measure ANOVAs were utilized in this investigation and included the following: 
1. Vertical Jump Height: Time [ Baseline, Immediate, Day 3, Post] X Treatment (Placebo 
vs. WWB) 
2. Ground Contact: Time [ Baseline, Immediate, Day 3, Post] X Treatment (Placebo vs. 
WWB) 
3. Peak Power: Time [ Baseline, Immediate, Day 3, Post] X Treatment (Placebo vs. WWB) 
4. Peak Velocity: Time [Baseline, Immediate, Day 3, Post) X Treatment (Placebo vs. 
WWB) 
5. Right Thigh Circumference: Time [Baseline, Immediate, Day 3, Post) X Treatment 
(Placebo vs. WWB) 
6. Left Thigh Circumference: Time [Baseline, Immediate Day 3, Post) X Treatment 
(Placebo vs. WWB) 
7. Right Pressure Pain Threshold: Time [Baseline, Immediate, Day 3, Post) X Treatment 
(Placebo vs. WWB) 
8. Left Pressure Pain Threshold: Time [Baseline, Immediate, Day 3, Post) X Treatment 
(Placebo vs. WWB) 
9. VAS Calf: Time [Baseline, Day 1, Day 2, Day 3, Day 4, Day 5, Post) X Treatment 
(Placebo vs. WWB) 
10. VAS Quadriceps: Time [Baseline, Day 1, Day 2, Day 3, Day 4, Day 5, Post) X Treatment 
(Placebo vs. WWB) 
11. VAS Hamstrings: Time [Baseline, Day 1, Day 2, Day 3, Day 4, Day 5, Post) X Treatment 
(Placebo vs. WWB) 
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12. VAS Gluteal Muscles: Time [Baseline, Day 1, Day 2, Day 3, Day 4, Day 5, Post) X 
Treatment (Placebo vs. WWB) 
The main effects were analyzed for all variables that showed no significant interaction 
effects. For a significant main effect, all pairwise comparisons were examined with a 
Bonferroni correction. Cohen’s d was calculated to determine effect size (d) between days 
and interpreted as 0.2, 0.5 and 0.8 for small, medium, and large effects. Participant 
demographics were compared using an independent-t test. The alpha (α) level was set at 0.05. 









4.1 Descriptive Statistics 
Twenty-five healthy males (n = 10) and females (n =15) took part in this investigation. Fourteen 
were randomly placed in the placebo group (male: 6; female: 8) and 11 in the WWB (male: 4; 
female: 7) group. The results of the independent t-test revealed no significant differences (p > 
0.05) between the groups in age, height, weight, and body mass index (BMI) (Table 1). All 25 
participants reported no adverse effects during the investigation. The compliance rate at the end 
of the study was comparable between groups. The placebo group had a compliance of 98.71% 
and the WWB group had a compliance of 98.18%. 
Table 1. Demographic Data 
 Placebo WWB p - value 
Age (yrs.) 19.93 ± 10.29 20.37 ± 1.29 0.316 
Height (cm) 170.91 ± 10.29 168.97 ± 10.22 0.643 
Weight (kg) 74.54 ± 17.51 72.86 ± 12.30 0.787 
BMI (kg/m2) 25.35 ± 5.37 25.57 ± 4.75 0.918 
Mean ± SD; yrs.: years; cm: centimeters; kg: kilograms; kg/m2 kilogram per meter squared; 
WWB: white willow bark; BMI: body mass index.  
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4.2. Muscle Soreness and Discomfort 
 
4.2.1. Hamstring Muscle Soreness 
The results revealed no significant hamstring muscle soreness and condition interaction (p > 
0.05). However, there was a significant main effect of time on hamstring muscle soreness F (1.82, 
32.82) = 24.250, p < 0.001 (Tables 2-3, Figure 4) 
    
Figure 4. Comparison of hamstring muscle soreness for participants in both the WWB and 
placebo groups over time.*Significant main effects of Time (collapsed across groups), VAS: 
visual analog scale; mm: millimeters; WWB: white willow bark. 
 
4.2.2.  Gluteal Muscle Soreness 
The results revealed no significant gluteal muscle soreness and condition interaction (p > 0.05). 
However, there was a significant main effect of time on gluteal muscle soreness F (2.82, 50.82) = 
























   
Figure 5. Comparison of gluteal muscle soreness for participants in both the WWB and placebo 
groups over time. *Significant main effects of Time (collapsed across groups), VAS: visual 
analog scale; mm: millimeters; WWB: white willow bark. 
 
4.2.3. Gastrocnemius Muscle Soreness 
The results revealed no significant gastrocnemius muscle soreness and condition interaction (p > 
0.05). However, there was a significant main effect of time on gastrocnemius muscle soreness F 























    
Figure 6 Comparison of gastrocnemius muscle soreness for participants in both the WWB and 
placebo groups over time. *Significant main effects of time (collapsed across groups), VAS: 
visual analog scale; mm: millimeters; WWB: white willow bark. 
 
4.2.4. Quadriceps Muscle Soreness 
The results revealed no significant quadriceps muscle soreness and condition interaction (p > 
0.05). However, there was a significant main effect of time on quadriceps muscle soreness F 





















    
Figure 7. Comparison of quadriceps muscle soreness for participants in both the WWB and 
placebo groups over time.*Significant main effects of time (collapsed across groups), VAS: visual 
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Placebo 
% Diff Prev. 
Day 
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3.20 ± 9.14 
-80.02% 
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   Gluteal     
 Baselinebcde Day 1adefg Day 2adefg Day 3abcefg Day 4abcdfg Day 5bcde Postbcde 
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   Gastrocnemius     
 Baselineb Day 1aefg Day 2 Day 3 Day 4b Day 5b Postb 
Placebo 
% Diff Prev. 
Day 










1.05 ± 2.48 
-70.00% 







% Diff Prev. 
Day 
0.09 ± .30 
 
6.82 ± 9.18 
7477.78% 
2.93 ± 4.02 
-57.04% 
1.74 ± 3.43 
-40.61% 
.46 ± 1.21 
-73.56% 
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   Quadriceps     
 Baselinebcedf Day 1cdef Day 2abfg Day 3abefg Day 4abfg Day 5abcdeg Postacdef 
Placebo 
% Diff Prev. 
Day 
0.88 ± 1.17 3.73 ± 5.54 
323.86% 














% Diff Prev. 
Day 
0.10 ± .54 
 
 


















0.78 2.31 18.38 15.53 4.08 2.89 1.52 
Mean ± SD; * significant main effect of time (collapsed across groups) (p < 0.05); WWB: white willow 
bark; mm: millimeters. 
a: a significant time difference from baseline           
b: a significant time difference from day 1                                                                                                                     
c: a significant time difference from day 2                                                                                                                           
d: a significant time difference from day 3                                                             
e: a significant time difference from day 4                                                                                                                             
f: a significant time difference from day 5                                                                                                                                












4.3 Pressure Pain Threshold 
The results revealed no significant pressure pain threshold and condition interaction for both the 
left and right mid-thighs (p > 0.05). However, there was a significant main effect of time for the 
right mid-thigh, F (3, 60) = 3.399, p = 0.02 (Table 2, Figure 8). In comparison, there was no 
significant main effect of time for the pressure pain threshold for the left mid-thigh (p = 0.207) 
(Tables 4-5; Figure 9). 
          
Figure 8. Comparison of right thigh pressure threshold for participants in both the WWB and 


































Figure 9: Comparison of left thigh pressure threshold for participants in both the WWB and 
placebo groups over time. oz.: ounces 
 
4.4 Mid-Thigh Circumference  
The results revealed no significant mid-thigh circumference and condition interaction for both the 
left and right mid-thighs (p > 0.05). However, there was a significant main effect of time for the 
right mid-thigh circumference, F (3, 66) = 7.135, p < 0.001 (Table 2, Figurer 10). Furthermore, 
there was a significant main effect for the left mid-thigh circumference, F (3, 69) = 15.784, p < 



























    
Figure 10. Comparison of right thigh circumference for participants in both the WWB and 
placebo groups over time. *Significant main effects of Time (collapsed across groups), VAS: 
visual analog scale; cm: centimeters. 
 
    
Figure 11. Comparison of left thigh circumference for participants in both the WWB and placebo 































































 Placebo WWB 




% diff pre 
53.51 ± 5.40 
1.77% 
53.36 ± 3.99 
1.58% 
Day 3 Mean 
% diff pre 
52.76 ± 5.26 
0.34% 
 
53.14 ± 4.55 
1.16% 
Postb Mean 
% diff pre 
52.50 ± 5.30 
0.15% 





   
Baselineb Mean 52.89 ± 5.42 52.53 ± 4.43 
Immediateacd Mean 
% diff pre 
54.07 ± 5.78 
2.23% 
 
53.41 ± 3.89 
1.68% 
Day 3b Mean 
% diff pre 
53.17 ± 5.30 
1.89% 
53.01 ± 4.18 
0.91% 
Postb Mean 
% diff pre 
52.93 ± 5.97 
0.08% 




   
Baseline Mean 187.61 ± 35.68 204.30 ± 46.94 
Immediate Mean 
% diff pre 
177.86 ± 51.28 
-5.20% 
 
198.07 ± 50.96 
-3.05% 
Day 3d Mean 
% diff pre 
161.79 ± 44.50 
-13.76% 
200.81 ± 44.59 
-1.71% 
Postc Mean 
% diff pre 
196.69 ± 45.89 
4.84% 




   
Baseline Mean 188.40 ± 37.41 212.46 ± 27.08 
 
Immediate Mean 
% diff pre 
180.56 ± 30.09 
-4.16% 
 
213.54 ± 42.15 
0.51% 
Day 3 Mean 
% diff pre 
169.51 ± 53.38 
-10.03% 
204.63 ± 35.16 
-3.69% 
Post Mean 
% diff pre 
197.27 ± 45.03 
4.71% 






Mean ± SD; * significant main effect of time (collapsed across groups) (p < 0.05); WWB: white 
willow bark; sec: seconds; oz.: ounces. 
a: a significant time difference from baseline                                                                             
b: a significant time difference from immediate                                                                                      
c: a significant time difference from day 3                                                                                             







 Table 5. Effect Size (d) Between Days for Parameters of DOMS 
 BL & IR BL & D3 BL & Post IR & D3 IR & Post D3 & Post 
PPT-R 0.12 0.10 0.32 0.01 .40 0.37 
PPT-L 0.01 0.24 0.16 0.21 0.11 0.36 
TC-R 0.19 0.17 0.01 0.008 0.18 0.16 




7.5 Athletic Performance  
 
4.5.1 Jump Height 
The results revealed no significant jump height and condition interaction (p > 0.05). However, 
there was a significant main effect for time F (1.916, 42.142) = 26.479, p < 0.001 (Tables 6-7; 
Figure 12)
 
  Figure 12. Comparison of jump height for participants in both the WWB and placebo groups 



























PPT-R: pressure pain threshold for right mid-thigh; PPT-L: pressure pain threshold for left mid-thigh; TC-R: 




4.5.2 Ground Contact Time 
The results revealed no significant ground contact time and condition interaction (p > 0.05). 
However, there was a significant main effect of time F (1.823, 40.115) = 7.743, p = 0.002 (Table 
6-7, Figure 13). 
    
Figure 13. Comparison of ground contact time for participants in both the WWB and placebo 
groups over time. *Significant main effects of Time (collapsed across groups); sec: seconds 
 
4.5.3 Peak Power  
The results revealed no significant peak power and condition interaction (p > 0.05). However, 

















   
Figure 14. Comparison of peak power for participants in both the WWB and placebo groups over 
time. *Significant main effects of Time (collapsed across groups); W: Watts. 
 
4.5.4 Peak Velocity 
The results revealed no significant peak velocity and condition interaction (p > 0.05). However, 
there was a significant main effect of time F (3, 66) = 21.660, p < 0.001 (Tables 6-7, Figure 15).  
    
Figure 15. Comparison of peak velocity for participants in both the WWB and placebo groups 









































Table 6.  Athletic Performance Parameters Prior and After DOMS 
Jump Height (cm) *  Placebo WWB 
Baselinebc Mean 33.27 ± 8.07 34.01 ± 9.47 




% diff pre 
28.01 ± 11.48 
-15.81% 
27.06 ± 13.15 
-20.44% 
Day 3ab Mean 
% diff pre 
30.58 ± 7.45 
-8.09% 
 
31.43 ± 11.45 
-7.59% 
Postb Mean 
% diff pre 
32.33 ± 8.17 
-2.83% 




   
Baselineb Mean 0.63 ± 0.18 0.68 ± 0.13 
Immediateacd Mean 
% diff pre 
0.76 ± 0.23 
20.63% 
 
0.69 ± 0.17 
1.47% 
Day 3b Mean 
% diff pre 
0.63 ± 0.17 0.66 ± 0.17 
-3.03% 
Postb Mean 
% diff pre 
0.63 ± 0.13 0.65 ± 0.16 
4.41% 
Peak Velocity (m/s)*    
Baselinebc Mean 2.23 ± .40 2.11 ± 0.36 
Immediateacd Mean 
% diff pre 
1.94 ± 0.42 
-13.00% 
 
1.92 ± 0.50 
-9.00% 
Day 3ab Mean 
% diff pre 
2.19 ± 0.36 
-1.79% 
1.95 ± 0.45 
-7.58% 
Postb Mean 
% diff pre 
2.20 ± 0.42 
-1.35% 
2.06 ± 0.42 
-2.37% 
Peak Power (W)*    
Baselinebc Mean 1629.93 ± 485.30 1470.70 ± 302.31 
 
Immediateacd Mean 
% diff pre 
1430.50 ± 494.99 
-12.24% 
 
1336.50 ± 343.87 
-9.12% 
Day 3abd Mean 
% diff pre 
1548.79 ± 471.58 
-4.98% 
1365.80 ± 348.67 
-7.13% 
Postbc Mean 
% diff pre 
1598.21 ± 493.77 
-1.95% 
1429.40 ± 301.79 
-2.81% 
  Mean ± SD; * significant main effect of time (collapsed across groups) (p < 0.05); WWB: white 
willow bark; sec: seconds; W: watts; m/s: meters per second; cm: centimeters. 
a: a significant time difference from baseline                                                                                              
b:a significant time difference from immediate                                                                                             
c: a significant time difference from day 3                                                                                                    




Table 7. Effect Size (d) Between Days for Athletic Performance 
 BL & IR BL & D3 BL & Post IR & D3 IR & Post D3 & Post 
JH 0.57 0.29 0.08 0.31 0.50 0.20 
GCT 0.41 0.06 0.13 0.43 0.50 0.06 
PP 0.37 0.27 0.06 0.10 0.30 0.21 
PV 0.56 0.43 0.10 0.16 0.45 0.33 
 JH: jump height; GCT: ground contact time; PP: peak power; PV peak velocity; BL: baseline; IR: immediate 







To the best of our knowledge, this was the first investigation to examine the effects of 
white willow bark (WWB) on the parameters of DOMS. Pain, swelling, and loss of muscle 
function following eccentric exercise are the trademarks of inflammation (Smith, 1991). In the 
current investigation, when collapsed across groups, the significant decrease (p < 0.05) in vertical 
jump height, peak power, peak velocity, and increase in ground contact time and thigh 
circumference immediately following DOMS indicates inflammation had occurred (Fridén et al., 
1983; Smith, 1991) The immediate changes following exercise verifies that the training protocol 
was effective in fatiguing the legs. The primary findings of this investigation demonstrate WWB 
may decrease subjective muscle soreness better than the placebo (Table 2; Figures 4-7). 
Moreover, WWB appears to blunt the decrease in pressure pain threshold that often accompanies 
muscle damage. While not significant (p > 0.05), the WWB group pressure pain threshold was 
higher than the placebo group 72hrs following the muscle damaging exercise protocol. The 
secondary findings of this investigation are inconclusive regarding the ability of WWB to 
promote a faster recovery of muscle function and the preservation of athletic performance. No 
difference (p > 0.05) was found between the treatment conditions for jump height, ground contact 





Both groups resulted similar detrimental effects following DOMS on performance and were 
almost evenly matched on their rate of muscle recovery and improvements in performance during 
the investigation.  
 
5.1 Muscle Soreness and Discomfort 
While not significant (p > 0.05), the consumption of WWB following an exhaustive bout 
of resistance training may decrease subjective muscle soreness or pain greater than the placebo in 
healthy individuals (Table 2, Figures 4-7). It all time frames, except for day-five for the 
gastrocnemius muscle, the rating of muscle soreness or discomfort was lower than that of the 
placebo. During the peak (approximately 48hrs following exercise) of gluteal muscle soreness, 
the placebo group rating of muscle soreness or discomfort was 21.53% higher than that of the 
white willow bark (77.18 ± 17.82mm; 60.56 ± 26.88mm, respectively). In both groups, hamstring 
muscle soreness peaked within 24hrs of exercise and the placebo group was 28.35% more sore 
than those in the WWB group (44.80 ± 26.96mm; 32.10 ± 28.81mm respectively). Peak soreness 
for the quadriceps in both groups occurred on day three (72 hours) following resistance training. 
While not statistically significant, the WWB group rated their muscle soreness 22.53% lower than 
the placebo (53.40 ± 31.43mm; 68.93 ± 27.51mm respectively). Unexpectedly, following the five 
days of supplementation, the quadriceps muscle soreness remained elevated from baseline in both 
the WWB (pre: 0.10 ± 0.54mm; post: 7.50 ± 8.41mm) and the placebo (pre: 0.88 ± 1.17mm; post 
9.02 ± 10.84mm) groups. This residual muscle soreness could be explained due to the quadriceps 
being the primary muscle activated during lunges and seated leg press. The trend of WWB being 
superior to placebo in decreasing subjective muscle soreness is in agreement with other studies 
that examined the effectiveness of willow bark on decreasing pain (Biegert, et al 2004; Churbasik 
et al 2000; Schmidt et al 2001). Biegert, et al (2004) found that willow bark decreased joint pain 
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more than the placebo after six weeks of treatment (15% vs. 4% respectively). Schmidt et al 
(2001) found after two weeks of consuming of 240mg salicin osteoarthritis pain was decreased by 
14% while those in the placebo group had a 2% increase in pain. Churbaskik et al (2000) 
concluded that WWB with a salicin content ranging from 120mg-240mg provided significantly 
more pain reduction than placebo. However, caution should be warranted with interpreting the 
results since participants were allowed to take tramadol as a rescue medication.  
 
5.2 Pressure Pain Threshold 
Pressure pain threshold is believed to correlate with an individuals’ perceived pain 
intensity (Fleckenstein et al., 2017). The results showed no significant (p > 0.05) difference 
between the groups on mid-thigh pressure pain threshold (Table 2, Figure 8-9). The WWB group 
pressure pain threshold was considerable higher than the placebo group 72hrs following 
resistance training. In the WWB group, 72hrs after exercise, both right and left mid-thigh 
pressure pain threshold was lower than what it was at baseline (3.05% and 3.69% respectively). 
In comparison, in the placebo group, right mid-thigh pressure pain threshold was 13.76% lower 
than baseline and the left mid-thigh 10.03% lower than baseline. When collapsed across groups, 
there was a significant (p < 0.05) time difference for right mid-thigh pressure pain threshold with 
day three (72hrs) following resistance training and significantly lower than day six (post). This is 
in agreement with results from an investigation by Fleckenstein et al (2017) that found pressure 
pain threshold was significantly lower at both 48 and 72 hours following DOMS. The decrease in 
pressure pain threshold may be due to the release of endogenous substances following muscle 
damage which desensitize muscle nociceptors mechanical stimulations (Mense, 2009) or an 
increase in mechanical sensitivity due to inflammation allowing high-threshold mechanosensitive 
receptors (HTM) to become susceptible to weaker stimuli (Diehl,1992). The data suggest that 
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willow bark shows a potential to maintain pressure pain threshold following exercise because 
those in the WWB group exhibited remarkably higher pressure pain threshold 72hrs following 
exercise. 
 
5.3 Mid-Thigh Circumference 
This is the first study to examine the effects of WWB on thigh circumference. Thigh 
circumference was used to measure the acute inflammatory response that occurs following 
DOMS. Assessing circumference is often used in research to measure the changes in 
inflammation over time (Manimmanakorn et al., 2016; Kazunori Nosaka & Clarkson, 1996; 
Tanabe et al., 2015). Measurements of thigh circumferences are an indicator of acute changes in 
the thigh volume due to inflammation associated with exercise induced muscle injury (Nosaka & 
Clarkson, 1995). In the current investigation, an increase in mid-thigh circumference developed 
quickly following the cessation of exercise and continued to stay elevated compared to baseline 
during the five days of supplementation. The immediate inflammatory response resulting in an 
increase in thigh circumference is consistent with other studies that examined acute responses of 
DOMS on parameters of muscle damage (Manimmanakorn et al., 2016; Kazunori Nosaka & 
Clarkson, 1996; Tanabe et al., 2015).  
The results of this study found no significant (p > 0.05) difference between the two 
treatments (Table 3, Figures 10-11). However, further analysis revealed the immediate right and 
left mid-thigh circumference was significantly (p < 0.05) greater following resistance training 
when collapsed across groups. Peak thigh circumference occurred immediately following 
exercise and was significantly higher than the baseline value. In the WWB group, immediately 
following exercise, right mid-thigh circumference was 1.58% higher than baseline and the left 
mid-thigh was 1.68% higher than baseline. In comparison, in the placebo, both right and left mid-
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thigh circumference increased following training (1.77% and 2.23% respectively). During this six 
day study, both groups showed a similar pattern of declining inflammation following training. 
Thigh circumference for both treatment conditions were similar across time. Due to no obvious 
differences between the two treatment conditions, the effect of WWB deceasing inflammation 
assessed by thigh circumference is inconclusive. Future studies should examine thigh 
circumference and markers of inflammation such as IL-6, IL-8 or IL-β to further investigate 
WWB effectiveness in decreasing inflammation.  
 
5.4 Athletic Performance  
This was the first investigation to examine the effects of WWB on the ability to maintain 
athletic performance following DOMS. Jump height provides an index of muscle power of the 
lower limbs (Nicol et al., 2015) and following a fatiguing exercise evaluates the recovery of the 
neuromuscular function. In this study, a four countermovement jump test was utilized. The results 
from this investigation revealed no significant (p > 0.05) differences between treatment groups in 
regards to jump height, ground contact time, peak velocity, or peak power following exercise 
(Table 4; figures 12-15). Further analysis revealed, when collapsed across groups, there was a 
significant (p < 0.05) main effect of time. The baseline jump height was significantly higher than 
both immediately and 72hrs (day three) following resistance training. In addition, ground contact 
time was significantly lower immediately following exercise compared to baseline, 72hrs (day 
three) and post supplementation (day six) regardless of condition.  
As anticipated, the jump height measurement immediately following exercise confirmed 
that the participants’ lower legs were fatigued. For WWB group, jump height decreased by 
20.44% and ground contact time increased by 1.47%. The immediate response for the placebo 
group was similar in which jump height decreased by 15.81% with ground contact time 
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increasing by 20.63%. These results agree with other’s (Bryane and Eston 2002; Caldwell et al., 
2018) which showed that following eccentric exercise, jump height was significantly lower 
immediately following exercise. Following the five-day supplementation period, the placebo 
group’s jump height was 2.83% lower than baseline and WWB was only 1.56% lower than 
baseline. Both groups had similar patterns of recovery regarding peak power and peak velocity 
with day six (post) measurement slightly lower than baseline. In fact, compared to baseline, the 
placebo group (peak velocity: -1.35%; peak power: -1.95%) showed a slightly better recovery 
than the WWB (peak velocity: -2.37%, peak power: -2.81%) on both variables. The conclusion 
on the ability of WWB to enhance muscle recovery following DOMS in inconclusive. 
 
5.5 Conclusion 
The purpose of this study was to compare the effects of WWB to a placebo on the 
parameters of DOMS following an exhaustive lower leg resistance training session. To the best of 
our knowledge, this is the first study to investigate the potential of WWB in decreasing both pain 
and inflammation following exercise in healthy adults. After the five-day supplementation period 
following the induction of DOMS, there were no significant difference between the treatment 
conditions on any variable. Despite not being statistically significant, WWB decreased subjective 
pain and soreness evaluated by the VAS and preserved pressure pain threshold more than the 
placebo. For all daily measurements during the five-day supplementation period, those in the 
WWB group rated their muscle discomfort lower than the placebo with a pronounced lower VAS 
rating for muscle soreness or discomfort 24-72hrs following exercise.  
Using a VAS to rate individual soreness is shown to be reliable and is used in previous 
investigations regarding DOMS and pain (Hoseinzadeh et al., 2015; Pumpa et al., 2013; Wheeler 
& Jacobson, 2013). The subjective nature of these scales should be discussed. The ability to deal 
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with pain and discomfort will vary among individuals and may be influenced by their current and 
past training experiences. Dealing with pain or discomfort is reflected to the individuals’ pain 
threshold and their ability to cope with both the mental and physical manifestations of pain (pain 
tolerance) (Pen et al., 1995). While there is no difference in pain threshold in athletes and no-
athletes, athletes have a superior pain tolerance over non-athletes (Azevedo & Samulski, 2003). 
In addition, trained individuals are shown to have more control over the debilitating effects of 
muscle soreness compared to novice (Pen et al., 1995). While the exact mechanism leading to an 
athletes’ superior pain tolerance is not known, it is suggested that both current and past athletes 
have developed superior cognitive coping strategies to redirect their focus (dissociation) or focus 
on the pain to reinterpret it (association)(Azevedo & Samulski, 2003; Pen et al., 1995). While 
none of the participants were actively taking part in a lower body resistance training program at 
the time of the study, their past training history may have had an influence on their perceived 
muscle soreness and discomfort. While their pain threshold was similar, those accustomed to the 
feeling of DOMS may have rated this perceived muscle soreness or discomfort as minimal 
compared to those with less experience of DOMS or with a lesser cognitive coping strategy.  
The placebo effect may have influenced the ratings of subjective muscle discomfort or 
pain following DOMS. The placebo effect is a powerful phenomenal aspect that can influence the 
physiological mechanisms and outcomes of pain (Colloca, 2019). For instance, in a study by 
Levine and colleagues (1981) postoperative patients recovering from molar extractions received 
either saline (placebo) or 6-8mg of morphine. The results showed that both groups of patients 
experienced a similar degree of pain relief. In an investigation by Carvalho et al. (2016) patients 
suffering from chronic low back pain were given an open label placebo prescription to take with 
their treatment as usual. At the end of the three week study, those patients taking the label 
placebo prescription experienced significant (p < 0.05) pain relief and a decrease in back pain-
related disability more than those who continued their treatment as usual only. The consumption 
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of a possible analgesic medication along with an expectation that the medication is going to 
provide relief can lead to an analgesic response (Rossettini et al., 2018). In comparison, the 
administration of an analgesic medication with no expectations of pain relief can lead to 
exacerbation of pain (Rossettini et al., 2018). In this investigation, 60% of participants regardless 
of group believed they had the WWB and 40% of the participants believed they had the placebo. 
When the data was broken down into individual treatment groups, 25% of those in the placebo 
believed they had the WWB and 36% in the WWB correctly guessed they had WWB. The 
participants belief that they were consuming WWB, regardless of grouping, may resulted in a 
lower pain rating due to their belief that the supplement or placebo was working. In addition, 
neutral stimulus such as the color, taste, or smell of the supplement could have led to the 
association of taking an analgesic and enhancing the pharmacological effect of the supplement 
(Colloca, 2019). Research has shown that white placebo pills are perceived as analgesics and 
large capsules are perceived to offer stronger pharmacological effects (Turner et al., 1994). In this 
investigation, the placebo pills contained powdered sugar in large capsules. The appearance of the 
placebo in this investigation could have led to the belief that they had the WWB and resulted in a 
perceived analgesic effect. Future investigations on the effect of WWB on DOMS should have a 
control that does not receive treatment to counteract any influences of a placebo effect. 
Quadriceps muscle soreness peaked on day three (72 hrs.) following exercise. This 
correlated with the significant decrease in pressure pain threshold observed on day three for the 
right mid-thigh. The pressure pain threshold for day three in the placebo group was 5.20% and 
10.03% lower than the baseline measurements for the right and left mid-thigh, respectively. 
WWB was able partially eliminate the detrimental effects that inflammation and muscle damage 
had on pressure pain threshold. The average pressure pain threshold in the WWB was 1.71% and 
3.69% lower than baseline during the peak of muscle soreness for the right and left mid-thigh 
respectively. The results of the investigation revealed, while not statistically significant, WWB 
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was superior to the placebo in maintaining pressure pain threshold. Furthermore, the ability of 
WWB to decrease inflammation which was evaluated by thigh circumference remains 
inconclusive. Thigh circumference was significantly higher immediately following exercise 
compared to both baseline and post-supplementation (day six). Both groups showed similar 
patterns of declining inflammation during this investigation as DOMS resolved on its own. In 
addition, during the five days of supplementation, none of the participants reported any adverse 
events while taking the supplement. This may confirm that WWB is tolerated better than NSAIDs 
or aspirin. This is in agreement with other studies that concluded that WWB is tolerated with no 
or mild side effects (Saller et al., 2008; Uehleke et al., 2013). 
There results of the investigation reveal that the ability of WWB to maintaining athletic 
performance following an exhaustive bout of exercise is inconclusive. Both the WWB and 
placebo showed similar trends in the peaking of deliberating effects and had similar rate of 
recovery following the induction of DOMS. Both groups had the largest decrease in jump height, 
peak power, and peak velocity and the longest ground-contact time immediately following 
exercise suggesting the participants’ legs were fatigued. Unexpectedly, the placebo group showed 
a trend to being slightly superior to WWB in recovery of athletic performance. Perhaps, 
motivation played a greater role than skeletal muscle soreness and damage during the four 
counter-movement repeated jumps when participants were asked to give maximal effort. Taken 
together, our findings conclude that WWB may offer some analgesic effects following a bout of 
exhaustive exercise as observed by the lower VAS scores and increased pressure pain threshold 
compared to the placebo. However, the ability of WWB to enhance recovery from skeletal muscle 
damage following exhaustive exercise, improve athletic performance and its ability to decrease 
inflammation remains inconclusive.  
There were limitations that need to be considered in the present study. The primary 
limitation of the current study was the small sample size. It is speculated that increasing the 
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sample size may have elicited significant differences between the groups regarding the subjective 
rating of muscle soreness or discomfort and the pressure pain threshold. In addition, measuring 
thigh circumference, pressure pain threshold and assessing athletic performance at both 24hrs and 
48hrs following training may have revealed significant difference between the treatment 
conditions. A secondary limitation in the study is the lack of a control group. The placebo effect 
may have impacted the VAS scores and pressure pain threshold. The inclusion of a control group 
that did not take part in any treatment could bring more clarity on the analgesic effects of WWB 
by counteracting the placebo effect that may have occurred. The addition measuring 
inflammatory cytokines such as IL-6, IL-8, or TN-α can help determine the effects of WWB on 
inflammation in healthy adults. Future research will need to continue to study the analgesic and 
anti-inflammatory properties of WWB in non-clinical populations to determine if would be a 
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